

UC San Diego

UC San Diego Previously Published Works

Title

Role of corticotropin-releasing factor in alcohol and nicotine addiction

Permalink

<https://escholarship.org/uc/item/5dn1x1qt>

Authors

Simpson, Sierra

Shankar, Kokila

Kimbrough, Adam

et al.

Publication Date

2020-08-01

DOI

10.1016/j.brainres.2020.146850

Peer reviewed



HHS Public Access

Author manuscript

Brain Res. Author manuscript; available in PMC 2021 August 01.

Published in final edited form as:

Brain Res. 2020 August 01; 1740: 146850. doi:10.1016/j.brainres.2020.146850.

Role of Corticotropin-Releasing Factor in Alcohol and Nicotine Addiction

Sierra Simpson^{1,2}, Kokila Shankar^{1,2}, Adam Kimbrough, Ph.D.¹, Olivier George, Ph.D.^{1,*}

¹Department of Psychiatry, University of California, San Diego, School of Medicine, La Jolla, California, 92093.

²Department of Neuroscience, Scripps Research, La Jolla, California, 92037.

Abstract

The two most prevalent substance use disorders involve alcohol (alcohol use disorder) and nicotine (tobacco use disorder), which are often co-abused. Robust preclinical and translational evidence indicates that individuals initiate drug use for the acute rewarding effects of the substance. The development of negative emotional states is key for the transition from recreational use to substance use disorders as subjects seek the substance to obtain relief from the negative emotional states of acute withdrawal and protracted abstinence. The neuropeptide corticotropin-releasing factor (CRF) is a major regulator of the brain stress system and key in the development of negative affective states. The present review examines the role of CRF in preclinical models of alcohol and nicotine abuse and explores links between CRF and anxiety-like, dysphoria-like, and other negative affective states. Finally, the present review discusses preclinical models of nicotine and alcohol use with regard to the CRF system, advances in molecular and genetic manipulations of CRF, and the importance of examining both males and females in this field of research.

Keywords

stress; anxiety; substance use disorder; sex differences; neuropeptide; extended amygdala

Introduction

According to the *Diagnostic and Statistical Manual of Mental Disorders*, 5th edition, substance use disorders (SUDs) consist of a problematic pattern of use that results in impairments in daily life and noticeable distress (American Psychiatric Association, 2013). A 2018 report by the Substance Abuse and Mental Health Services Administration found that 26.7% of individuals 12 years of age and older used tobacco products in the past year,

*Correspondence: Dr. Olivier George, Department of Psychiatry, University of California, San Diego, School of Medicine, 9500 Gilman Drive, MC 0714, La Jolla, CA 92093-0737. olgeorge@ucsd.edu. Telephone: +1-858-822-0323.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Conflicts of Interest

The authors declare no conflicts of interest.

and 65.5% used alcohol (SAMHSA, 2018). Chronic nicotine and alcohol use results in the dysregulation of brain regions that are involved in stress and emotional systems upon the initiation and cessation of use. Corticotropin-releasing factor (CRF) is a critical regulator of stress systems, driving addiction-like behavior through activation of the hypothalamic-pituitary-adrenal (HPA) axis and extended amygdala. Activation of the CRF system results in anxiety-like behaviors, compulsive responding in paradigms of drug self-administration, and the stress-induced reinstatement of drug seeking in abstinent animals. Extensive clinical and preclinical research has explored the role of CRF in both alcohol use disorder (AUD) and tobacco use disorder.

Corticotropin-Releasing Factor System Overview

Corticotropin-releasing factor is a 41-amino-acid neuropeptide that is encoded by the *crh* gene, which was first discovered and characterized as a regulator of stress in 1981 by Vale et al. (Vale et al., 1981). CRF₁ and CRF₂ receptors and the urocortin family of related signaling peptides (urocortin-1 [Ucn1], Ucn2, and Ucn3) emerged thereafter as mediators of negative emotional states that are associated with the stress response (Vaughan et al., 1995; Zhao et al., 1998). Corticotropin-releasing factor is expressed throughout the central nervous system, including the paraventricular nucleus of the hypothalamus (PVN) and regions of the extended amygdala, comprising the central nucleus of the amygdala (CeA), nucleus accumbens (NAc), and bed nucleus of the stria terminalis (BNST; Fig. 1). Corticotropin-releasing factor-expressing neurons are also found throughout cerebral cortices, the paraventricular nucleus (PVN), the ventral tegmental area (VTA), the locus coeruleus (LC), the skin, and the gut (Dabrowska et al., 2016; Rodino-Janeiro et al., 2015). Corticotropin-releasing factor is regulated by CRF-binding protein (CRF-BP), a glycoprotein that regulates the binding of extracellular CRF to its receptors (Behan et al., 1995; Ketchesin and Seasholtz, 2015; Seasholtz et al., 2002). Humans express polymorphisms of CRF and CRF-BP that can have significant downstream effects on responses to withdrawal and stress (Barr et al., 2009; Hansson et al., 2007; Ketchesin and Seasholtz, 2015; Ketchesin et al., 2017). We and others have hypothesized that the CRF system plays an important role in SUDs by increasing the motivation to use drugs through neuronal activation in the extended amygdala to produce anxiety-like behavior, shifts in reward salience, compulsive-like drug self-administration, and the stress-induced reinstatement of drug seeking (Haass-Koffler and Bartlett, 2012; Koob, 2008; Koob, 2009; Koob, 2010).

CRF₁ and CRF₂ receptors belong to the secretin-receptor (class B1) subtype of the G protein-coupled receptor family. Each CRF receptor subtype is encoded by distinct genes and has several splice variants that are expressed in the central nervous system and peripheral tissues. CRF₁ and CRF₂ receptor expression has high overlap, with nearly 70% identical sequence conservation (Dautzenberg and Hauger, 2002). CRF₁ and CRF₂ receptor activation preferentially leads to initiation of the cyclic adenosine monophosphate second messenger pathway through the G α s protein activation of protein kinase A. In the case of CRF₁, after stressful tasks that elicit high levels of CRF secretion, females have been shown to exhibit preferential signaling through G α s, leading to increases in CRF sensitivity compared with males that exhibit preferential signaling via β -arrestin (Hauger et al., 2006;

Miguel et al., 2014; Van Pett et al., 2000). Other signaling pathways include activation of the extracellular signal-related kinase/mitogen-activated protein kinase cascade through β -arrestin (Punn et al., 2006), the $G_{\alpha q}$ activation of protein kinase C, and the AKT/protein kinase B pathway (Hauger et al., 2006); Fig. 2). Despite high sequence conservation, the CRF peptide has 10-fold higher affinity for CRF₁ receptors relative to CRF₂ receptors (Perrin et al., 1995). CRF₁ and CRF₂ receptors are widely expressed in the central nervous system, with extensive overlap in expression, but distinct expression profiles are also found between brain regions that are involved in addiction-like behaviors, such as the CeA and BNST (Van Pett et al., 2000); Fig. 1). These differences play an important role in the recruitment of downstream signaling pathways in SUDs. For a further in-depth review of intracellular signaling pathways, see Hauger et al. (Hauger et al., 2006).

Behavioral Effects of Manipulations of CRF, CRF Receptors, and Urocortin

Numerous studies have investigated the behavioral effects of manipulations of CRF and CRF₁ and CRF₂ receptors (Land et al., 2008; Zorrilla et al., 2013; Zorrilla et al., 2014). Table 1 presents a list of genetic and pharmacological manipulations of the CRF system with regard to stress and anxiety-like behavior. The central administration of CRF peptide and CRF receptor agonists in rodent models mimics behavioral responses to stress (Britton et al., 1986a; Britton et al., 1986b; Dunn and Berridge, 1990; Sutton et al., 1982). In contrast, CRF₁ receptor knockout mice exhibit less anxiety-like behavior and a decrease in recruitment of the HPA axis, despite having equal levels of stress hormones as control animals (Smith et al., 1998; Timpl et al., 1998). Similarly, CRF₁ receptor antagonists exert effects that are opposite to CRF, reducing both stress and anxiety-like behavior (Overstreet et al., 2004b; Zorrilla et al., 2002; Zorrilla and Koob, 2004). These alterations were demonstrated using various behavioral paradigms, including the elevated plus maze (Sahuque et al., 2006), forced swim test (Griebel, 2002), and measures of alcohol withdrawal (Funk et al., 2006; Gehlert et al., 2007) and nicotine withdrawal (Shaham and de Wit, 2016).

CRF₂ receptors are also expressed throughout the brain, including the olfactory bulb, the hippocampus, the amygdala, the septum, dorsal and median raphe nuclei, the cortex, the pituitary, and the spinal cord (Bittencourt and Sawchenko, 2000; Korosi et al., 2006; Van Pett et al., 2000). These regions are important for learning, memory, the stress response, reward, and pain, which are particularly relevant as negative consequences of withdrawal (Kim et al., 2011). CRF₂ receptor knockout mice exhibit higher sensitivity to stress and an increase in anxiety-like behavior compared with wildtype mice (Neufeld-Cohen et al., 2012). These knockout animals also exhibit the early termination of adrenocorticotrophic hormone (ACTH) release rather than the delayed initiation of HPA axis recruitment, similar to CRF₁ receptor knockout animals (Coste et al., 2000). Double knockout of both CRF₁ and CRF₂ receptors significantly blunts the stress response, but such an effect was attributed largely to CRF₁ receptor loss. Priel et al. reported that CRF₂ receptors were unable to compensate for CRF₁ receptor loss, suggesting that each CRF receptor subtype plays a different role in regulating the stress response (Preil et al., 2001).

Corticotropin-releasing factor-binding protein is an important modulator of the CRF/Urocortin system (Ucn). It is capable of binding to both CRF and urocortin-1 (Ucn1) with high affinity to inhibit CRF/Ucn1-induced ACTH secretion through sequestration. Corticotropin-releasing factor-binding protein has much lower affinity for Ucn2 and no affinity for Ucn3 (Haass-Koffler, 2018). Corticotropin-releasing factor-binding protein is found throughout the central nervous system and highly expressed in regions that are traditionally linked to addiction and stress-related behaviors, including the extended amygdala, hippocampus, and prefrontal cortex (Potter et al., 1992). Sex differences have also been reported in the localization and expression of CRF-BP. In females, estrogen and gonadotrophin-releasing hormone positively regulate CRF-BP expression in pituitary-related cell types. The positive regulation of CRF-BP has been correlated with an increase in negative behavioral outcomes, such as mood and anxiety disorders, which are often reported more in females than in males and are important in relapse behaviors (Westphal and Seasholtz, 2006). For additional reviews, see (Van Den Eede et al., 2005; Vandael and Gounko, 2019).

Urocortin-1, Urocortin-2, and Urocortin-3 are members of the CRF family. Urocortins have similar sizes as CRF (38–40aa), significant sequence homology to CRF, and similar binding properties as CRF. Urocortin-1 can bind to both CRF₁ and CRF₂ receptors, whereas Urocortin-2 and Urocortin-3 bind only to CRF₂ receptors (Fig. 2). Multiple urocortin knockout lines have been generated in mice. For example, Ucn1 knockout mice exhibited normal stress responses (Wang et al., 2002). Other Ucn1 knockout mouse lines did not exhibit the appropriate adaptation to repeated restraint stress as well as cold stress tests (Zalutskaya et al., 2007). Urocortin-1 and Ucn2 double-knockout lines exhibited robust anxiolytic phenotypes in the elevated plus maze and open field test (Neufeld-Cohen et al., 2010a). This response was hypothesized to be attributable primarily to CRF₁ receptor activation by Urocortin-1. Mice with the triple knockout of Urocortin-1, Urocortin-2, and Urocortin-3 exhibited an increase in the stress response 24 h following stress exposure but not under normal condition or immediately following acute stress exposure (Neufeld-Cohen et al., 2010a). Thus, the family of urocortins contribute to the stress response. Further review of the role of the urocortin peptide family in the stress response can be found elsewhere (Koob and Heinrichs, 1999; Ryabinin et al., 2012; Squillacioti et al., 2019; Wagner, 2019; Zorrilla EP, 2005).

In addition to pharmacological and genetic manipulations of CRF₁ and CRF₂ receptors, transgenic models in rats and mice have been developed and characterized as novel tools to manipulate viral vectors combined with optogenetic, chemogenetic, and fiber photometric approaches (Fuzesi et al., 2016; Kim et al., 2019; Pomrenze et al., 2015). These advances allow for visualization and targeted network manipulations that are receptor-, cell type-, and network-specific. The transgenic rat that was developed by Pomrenze et al. (2015) allows for the anatomical labeling of CRF neurons, which was previously difficult using traditional immunohistochemical techniques. The addition of Cre-recombinase in this model creates a tool to achieve cellular specificity in manipulations of CRF-expressing neurons (Pomrenze et al., 2015). Coupled with optogenetics, targeted populations of neurons can be activated or inhibited in awake, freely behaving animals. Additionally, Kim et al. optogenetically stimulated the PVN to gain a mechanistic understanding of biphasic CRF responses that

encode negative and positive valence (Kim et al., 2019). Other groups have used fiber photometry to visualize the activity of CRF-expressing neurons in awake, freely behaving animals, followed by the optogenetic interrogation of activity within these circuits (Fuzesi et al., 2016). These modern techniques have fostered a new generation of precise molecular approaches to study CRF, key neuronal circuits, and CRF-related behaviors.

Key Brain Regions Related to the CRF System

Corticotropin-releasing factor is widely distributed in the brain. Increases or decreases in CRF signaling in distinct brain regions can affect a wide range of behaviors. For example, the prefrontal cortex (PFC) is involved in impulse control, goal-directed behavior, and working memory (Devlbiss et al., 2016; Hupalo and Berridge, 2016; Kwako and Koob, 2017). This brain region also exhibits widespread functional and structural abnormalities in individuals with SUDs and sends downstream projections to regions that are involved in motivation, stress, mood, and impulsivity (Klenowski, 2018; Sesack et al., 1989; Zhang et al., 2012). The deletion of CRF₁ receptor signaling in the PFC ameliorates acute stress-induced impairments in executive function, such as impulse control and decision making (Bryce and Floresco, 2016; George et al., 2012; Hupalo et al., 2019; Uribe-Marino et al., 2016). Another macrostructure that has high CRF expression is the extended amygdala (i.e., CeA, NAc, and BNST; (Alheid and Heimer, 1988; Heimer and Alheid, 1991). The macrostructure of the extended amygdala is based on functional connectivity and has been shown to play a prominent role in both fear and anxiety-like behavior, two integral aspects of the stress response (Davis et al., 2010). The CeA is composed predominantly of γ -aminobutyric acid (GABA)ergic projection neurons and interneurons (Sun et al., 1994). The lateral CeA sends inhibitory projections to the medial CeA and also projects to the BNST, which is also implicated in stress and addiction-like behaviors (Krettek and Price, 1978; Weller and Smith, 1982). The CeA is a major source of CRF in the BNST, but the BNST also expresses high levels of CRF in the lateral region (Sakanaka et al., 1986). The medial CeA projects to the periaqueductal gray (PAG), which is involved in withdrawal-induced hyperalgesia (Avegno et al., 2018). The medial CeA also sends inhibitory projections to the hypothalamus, locus coeruleus, nucleus of the solitary tract, and pedunculopontine tegmental nucleus. Network connectivity within this region is positioned to regulate a wide range of behavioral processes, including the stress response and peripheral processes that are involved in somatic signs of withdrawal (Pitklnen and Amara, 2000)

The function of CRF in the PVN is essential for activation of the HPA axis. Cells within the PVN secrete CRF, which in turn activates the anterior pituitary to produce ACTH (Smith and Vale, 2006; Vale et al., 1981). Adrenocorticotrophic hormone then acts on adrenal cortical cells, resulting in the release of cortisol in humans and corticosterone in rodents (Herman et al., 2016). These hormones (cortisol/corticosterone) then activate glucocorticoid and mineralocorticoid receptors, which initiate intracellular responses to stress (Hauger et al., 2006). This pathway has been extensively characterized. The emergence of novel microcircuitry feedback in the PVN has been explored with regard to local CRF signaling in the PVN. Recent studies reported the presence of fast-responding microcircuitry that involves CRF and CRF₁-positive neurons in the PVN (Jiang et al., 2018a). These CRF₁-positive neurons make local GABAergic synapses on both magnocellular and parvocellular

cells in the PVN and long-range glutamatergic synapses on cells in the nucleus of the solitary tract. Jiang et al. ablated CRF₁-positive neurons in the PVN and observed an increase in the amount of corticosterone that was released in male rodents during stressful situations, and the duration of this elevation was longer than in intact animals (Jiang et al., 2018a). Further supporting that the long-range secretion of CRF plays a role in the stress response, but local activation is also important (Herman et al., 2016; Jiang et al., 2018a).

Corticotropin-releasing factor plays a role in various behaviors that are downstream of the stress response. Stressors have been shown to elicit dopamine-dependent behaviors that are associated with motivation and reward (Wanat et al., 2013). Dopaminergic neurons in the VTA are well known for their contribution to the rewarding effects of drugs of abuse. Downregulation of the mesolimbic dopamine system during withdrawal is common in SUDs and has been well studied in nicotine and cocaine use in both dependent and nondependent animals (Grieder et al., 2014). Intracerebral injections of CRF in the VTA promoted dopamine-dependent behaviors in drug-dependent animals, whereas drug-naive animals did not exhibit the same repression (Bryce and Floresco, 2016; Wanat et al., 2013).

Corticotropin-releasing factor function in the VTA and interpeduncular nucleus (IPN) plays an important role in dopamine signaling and motivated behavior. Both rodents and humans express a population of CRF neurons in the VTA that are recruited during withdrawal from nicotine after chronic exposure and contribute to dopaminergic adaptations that mediate negative motivational states that are elicited by nicotine withdrawal (Grieder et al., 2014). Chronic nicotine exposure has been shown to upregulate CRF mRNA expression in dopaminergic neurons in the posterior VTA, which can block CRF₁ receptors and nicotine-induced transient GABAergic inputs to those neurons. Grieder et al. reported that CRF peptide was depleted in the posterior VTA, IPN, and CeA but not in the anterior VTA or PVN during nicotine withdrawal (Grieder et al., 2014). Furthermore, Zhao-Shea et al. demonstrated that local signaling from the VTA to the IPN modulates glutamatergic inputs from the medial habenula and that the pharmacological blockade of IPN CRF₁-positive neurons using small molecules or optogenetic silencing of the medial habenular output to the IPN alleviated withdrawal-induced anxiety-like behavior (Zhao-Shea et al., 2015). These findings link the reward system and stress systems based on local circuitry within the VTA and IPN during withdrawal.

Modulation of Alcohol-Related Behaviors by CRF

Alcohol use disorder is a chronic disorder that is characterized by the loss of control over alcohol intake, withdrawal symptoms upon the cessation of alcohol use, and relapse after periods of abstinence (Becker, 2008; Weiss, 2005). The abrupt cessation of chronic alcohol intake in humans and animal models is associated with negative mood, irritability, and somatic signs of withdrawal, many of which are at least partially mediated by CRF signaling (Kimbrough et al., 2017; Schuckit, 2009). Chronic alcohol use affects brain stress systems through modulation of the HPA axis and extended amygdala (Koob, 2009). However, chronic activation of the CRF system in the PVN and extended amygdala is known to have opposite effects. Chronic stress and chronic exposure to alcohol are associated with downregulation of the CRF system in the PVN, leading to hyporeactivity of the HPA axis

and sensitization of the CRF system in the extended amygdala (Blaine et al., 2016; Breese and Knapp, 2016; Logrip et al., 2013; Piazza et al., 1993; Piazza and Le Moal, 1997; Rivier et al., 1984). Extensive pharmacological and genetic manipulations of the CRF system have been shown to play a fundamental role in alcohol-related behaviors. The section below focuses primarily on preclinical studies that explored the role of CRF in alcohol-related behaviors. Notably, however, small-molecule CRF receptor antagonists have been unsuccessful in the treatment of AUD in clinical trials (Kwako et al., 2015; Shaham and de Wit, 2016). For a further review of these trials, possible caveats, and alternative explanations (e.g., the role of other neuropeptides), see Gilpin (Gilpin, 2012).

Manipulation of the CRF System and Related Behaviors in Alcohol Use

The role of CRF transmission and stress in alcohol-related behaviors has been extensively examined using neurobiological, pharmacological, and genetic models (Table 2). Preclinical evidence of the anxiogenic properties of CRF has been documented, and humans with AUD often report that stress and anxiety motivate continued drinking (Ludwig and Wikler, 1974). High CRF₁ receptor expression was reported to be associated with stress-induced alcohol intake in genetically selected Marchigian Sardinian (msP) alcohol-preferring rats (Hansson et al., 2007) and nongenetically selected animals in a post-dependent state (Sommer et al., 2008). Genetic knockout animals exhibit a wide range of reductions of drinking behavior, and CRF₁ knockouts CRF₁/CRF₂ double knockouts exhibit the greatest behavioral effects (Kaur et al., 2012; Molander et al., 2012; Muglia et al., 1995; Pastor et al., 2008; Pastor et al., 2011; Preil et al., 2001; Smith et al., 1998).

During alcohol withdrawal, CRF release increases in the CeA and BNST in dependent rats (Funk et al., 2006; Olive et al., 2002). For example, Baldwin et al. injected CRF intracerebroventricularly (i.c.v.) and observed a reduction of open-arm entries in the elevated plus maze during alcohol withdrawal, indicating an increase in anxiety-like behavior (Baldwin et al., 1991). Furthermore, injections of CRF and CRF receptor agonists exacerbated alcohol withdrawal-induced stress (Bell et al., 1998; Huang et al., 2010), increased anxiety-like behavior in the elevated plus maze (Zhao et al., 2013), increased withdrawal-induced social anxiety (Overstreet et al., 2004b), and increased the footshock stress-induced reinstatement of alcohol seeking (Le et al., 2002).

The administration of CRF receptor antagonists has been shown to decrease alcohol drinking in alcohol-dependent animals but not in nondependent animals (Funk and Koob, 2007; Gilpin et al., 2008; Richardson et al., 2008). Bruijnzeel et al. showed that CRF receptor blockade with the nonselective CRF₁/CRF₂ receptor antagonist D-Phe CRF₁₂₋₄₁ prevented elevations of brain reward thresholds that were associated with alcohol withdrawal (Bruijnzeel et al., 2010). Similarly, local intracerebral and i.c.v. injections of small-molecule CRF₁/CRF₂ receptor antagonists selectively blocked dependence-induced increases in alcohol self-administration during acute withdrawal (Valdez et al., 2003; Valdez et al., 2004). The CRF₁ receptor antagonists CRA-1000 and MPZP blocked the increase in alcohol intake in response to acute withdrawal-induced stress (Funk et al., 2006; Knapp et al., 2004; Richardson et al., 2008). Injections of the CRF₂ receptor agonist Ucn3 in the CeA similarly reduced the increase in alcohol self-administration that was associated with acute

withdrawal (Funk et al., 2006; Funk and Koob, 2007; Sharpe and Phillips, 2009; Valdez et al., 2004). Thus, antagonism of the CRF system reduces alcohol drinking after acute withdrawal and protracted abstinence (Baldwin et al., 1991; Lodge and Lawrence, 2003; O'Callaghan et al., 2005; Rassnick et al., 1993). These results support the hypothesis that the dysregulation of CRF stress systems is only observed in alcohol-dependent individuals and not in nondependent or recreational drinkers (Le et al., 2000; Lowery and Thiele, 2010; Sarnyai et al., 2001; Shaham et al., 2000). For a further review of neurobiological and pharmacological differences between dependent and nondependent animals, see Vendruscolo and Roberts (Vendruscolo and Roberts, 2014).

In addition to models of chronic alcohol consumption and dependence, the drinking-in-the-dark (DID) and intermittent-access two-bottle choice (IA2BC) models have also been crucial for revealing the role of CRF in binge-like drinking behaviors. Binge-like drinking in DID and IA2BC paradigms has been shown to potentiate CRF₁ activity in regions of the brain that are involved in reward, such as the VTA and BNST (Sparta et al., 2013). Similar to models of alcohol dependence, the intra-VTA antagonism of CRF₁ receptors and activation of CRF₂ receptors decreased alcohol intake, which was eliminated by the simultaneous blockade of both receptor subtypes. The chemogenetic inhibition of local CRF neurons in the VTA did not alter binge-like alcohol drinking behavior, although the inhibition of VTA-projecting CRF-expressing neurons from the BNST significantly reduced intake (Rinker et al., 2017). Binge drinking was also suppressed by neuropeptide Y₁ receptor activation in the BNST, which enhanced inhibitory synaptic transmission in CRF-expressing neurons via a G_i-mediated, protein kinase A-dependent postsynaptic mechanism (Pleil et al., 2015). Similarly, in both mice and rats, intra-VTA administration of the CRF₁ receptor antagonist CP-154,526 selectively decreased alcohol intake in a two-bottle choice paradigm. CP-154,526 administration also suppressed alcohol drinking in high alcohol-preferring Long-Evans animals, regardless of brain site manipulation (Hwa et al., 2013). In a follow-up study, Hwa et al. found that the social stress-induced escalation of intermittent alcohol drinking was modulated by CRF₁ receptors in the VTA (Hwa et al., 2016). These findings confirmed that CRF₁ receptor blockade moderates escalated drinking in binge models and indicated that intermittent-access alcohol consumption could require interactions between CRF and dopamine in the VTA (Hwa et al., 2013). Thus, these studies demonstrate that excessive drinking can be reduced by CRF manipulations while non-escalated drinking remains intact.

Modulation of the CRF System and Anxiety/Stress during Alcohol Use

The blockade of CRF in the CeA has been shown to ameliorate elevations of anxiety-like behavior that are associated with alcohol withdrawal using both small molecules and cellular manipulations to inactivate CeA CRF-expressing neurons (de Guglielmo et al., 2016; Rassnick et al., 1993). Systemic (intraperitoneal [i.p.] or subcutaneous [s.c.]) or i.c.v. CRF receptor antagonist administration blocked anxiety-like responses to stressors during protracted abstinence (Albrechet-Souza et al., 2015; Breese et al., 2005; Valdez et al., 2003), whereas CRF receptor agonists increased alcohol self-administration that was associated with protracted abstinence (Funk et al., 2006; Valdez et al., 2003). Huang et al. reported that intracerebral injections of CRF in the CeA and BNST increased the stress response during

alcohol withdrawal (Huang et al., 2010). The lateral BNST contains CRF-expressing neurons (Cummings et al., 1983; Dabrowska et al., 2016; Morin et al., 1999; Sakanaka et al., 1986) and receives CRF-containing projections from the CeA (Sakanaka et al., 1986). Projections from the CeA to the BNST have also been shown to mediate anxiety-like behavior through the CRF activation of BNST CRF-expressing neurons (Pomrenze et al., 2019). The CRF system in the BNST has been shown to mediate the stress-induced reinstatement of drug-seeking behavior through both CRF₁ and CRF₂ receptors (Erb and Stewart, 1999). Functional studies found that the selective optogenetic stimulation of CRF₂-expressing neurons in the BNST ameliorated the adaptive stress response (Henckens et al., 2017). de Guglielmo et al. reported that the optogenetic inactivation of CRF-dependent amygdalofugal pathways in the BNST reversed addiction-like behaviors, including alcohol drinking and withdrawal signs, in alcohol-dependent rats (de Guglielmo et al., 2019). Corticotropin-releasing factor release increased in the CeA and BNST in alcohol-dependent rats (Funk et al., 2006; Olive et al., 2002), and CRF levels decreased after animals resumed drinking (Olive et al., 2002), likely through a negative reinforcement mechanism (i.e., the relief of withdrawal-induced stress). Direct pathways from the extended amygdala contribute to the stress response during alcohol use. The BNST sends extensive projections to the PVN and hypothalamic nuclei (Alheid and Heimer, 1988; Herman et al., 1994), suggesting that increases in extracellular CRF levels at the level of the BNST may also contribute to HPA axis activation that is commonly observed during alcohol withdrawal (Tabakoff et al., 1978). Therefore, targeting regions throughout the CRF system beyond the CeA may be an alternative strategy for the treatment of AUD. For a list of manipulations of the CRF system in alcohol use, see Table 2.

Modulation of Nicotine-Related Behaviors by CRF

Tobacco use is highly addictive because of the presence of nicotine. Cigarette smoking remains the leading preventable cause of death in the United States (Samet, 2013). Stress has been shown to promote the use of cigarettes and other tobacco products. The rewarding and cognitive-enhancing effects of nicotine play an important role in the initiation of smoking (Brujinzeel, 2012a; Rezvani and Levin, 2001). However, after the development of nicotine dependence, individuals continue to smoke to prevent negative emotional states, such as dysphoria and anxiety, that are associated with smoking cessation (Brujinzeel and Gold, 2005). This is supported by the observation that most smokers relapse during the first week of abstinence when affective withdrawal signs are most severe. Relapse rates have been shown to be higher in individuals with depression (Hughes et al., 2004; Jarvis, 2004), and smokers report that stress is the primary reason for relapse during protracted abstinence (Breese et al., 2005; Heilig et al., 2010). Similar to stressors and alcohol, acute nicotine exposure activates the HPA axis, but its impact on behavior depends on the dose and time of administration. For example, low doses of nicotine promote antidepressant effects and anxiolytic states (Andreassen et al., 2008; Balerio et al., 2005; Plaza-Zabala et al., 2010; Varani et al., 2012), whereas chronic exposure and high doses of nicotine have been shown to increase anxiety-like behavior, produce conditioned place aversion, and recruit PVN CRF-expressing neurons (File et al., 1998; Yu et al., 2008). Relative to AUD, far fewer preclinical studies have explored the role of CRF in tobacco use disorder, likely because explorations of

the role of CRF in alcohol drinking and AUD began much earlier compared with nicotine, and translational and preclinical models of nicotine intake were developed much later (Cohen et al., 2012; Cohen and George, 2013; Gilpin et al., 2014). Below is a discussion of the role of CRF in nicotine-related behaviors. For a comprehensive list of modulations of the CRF system in nicotine-related behaviors, see Table 3.

Modulation of the CRF System and Anxiety, Dysphoria, and Stress during Nicotine Use

Anxiety-like behaviors are commonly seen during withdrawal and protracted abstinence from nicotine. The role of CRF in mediating anxiety-like behavior has been shown to be specific to conditioned rather than unconditioned anxiety, indicating that CRF may be involved in negative reinforcement processes that lead to excessive use rather than the simple expression of withdrawal symptoms (Tucci et al., 2003). Manipulations of the CRF system in animal models of nicotine addiction have elucidated roles of both CRF peptide and CRF receptors in anxiety- and depression-like behaviors (Bruijnzeel, 2012b; Molas et al., 2017). Nicotine dependence has been repeatedly reported to increase CRF mRNA expression in the posterior VTA, measured by *in situ* hybridization (Cohen et al., 2015; Grieder et al., 2014; Slawecki et al., 2005). CRF₁ receptor blockade in the VTA prevented anxiety-like behavior during nicotine withdrawal (Grieder et al., 2014), and the upregulation of CRF in the VTA–interpeduncular nucleus–medial habenula circuit was involved in the increase in anxiety-like behavior during withdrawal (Zhao-Shea et al., 2015). George et al. found that abstinence from nicotine increased anxiety-like behavior and led to greater nicotine intake after abstinence, and CRF₁ receptor antagonism prevented this behavior (George et al., 2007). Interestingly, CRF₁ and CRF₂ receptors play opposing roles in anxiety-like behavior. Selective CRF₁ receptor antagonism reduced anxiety-like behavior (Grieder et al., 2014; Tunstall and Carmack, 2016; Zhao-Shea et al., 2015), whereas selective CRF₂ receptor agonism ameliorated negative affective states during chronic nicotine exposure and withdrawal symptoms in mice (Bagosi et al., 2016). Brain regions that have been shown to be involved in mediating this behavior include the VTA, NAc, amygdala, and hypothalamus (Grieder et al., 2014; Torres et al., 2015; Yu et al., 2008). Torres et al. also reported higher CRF levels in the NAc, amygdala, and hypothalamus in female rats than in male rats during nicotine withdrawal, although males had higher levels of corticosterone (Torres et al., 2013; Torres et al., 2015). Increases in CRF levels in the hippocampus have also been shown to mediate anxiety-like behavior following nicotine dependence (Slawecki et al., 2005). Altogether, CRF-mediated anxiety significantly contributes to nicotine dependence and perpetuates nicotine use through negative emotional states. Further dissections of circuitry and signaling pathways may contribute to the development of novel therapies for tobacco use disorder.

Dysphoria and other depressive-like symptoms are characterized in rodents primarily by measuring brain reward thresholds using intracranial self-stimulation. Animal studies that investigated the role of CRF in nicotine-induced dysphoria have reported a wide range of results. Bruijnzeel et al. found that the dysphoric state that was associated with nicotine withdrawal was at least partially mediated by high CRF levels in the CeA. Selective CRF₁

receptor antagonism in the CeA attenuated dysphoria-like behaviors during nicotine withdrawal (Bruijnzeel et al., 2009). Furthermore, a recent study reported that CRF receptor blockade in the CeA but not BNST prevented elevations of brain reward thresholds that were associated with nicotine withdrawal (Marcinkiewicz et al., 2009). However, Qi et al. found that CRF overexpression in the CeA diminished the dysphoric-like state that was associated with nicotine withdrawal (Qi et al., 2014). These conflicting results may be explained by differential neuroadaptive changes in CRF₁ and CRF₂ receptor gene expression. In both studies, the authors found that the ratio of CRF₁ to CRF₂ expression was altered, in which CRF overexpression decreased CRF₁ receptor expression and increased CRF₂ receptor expression. Another possibility is that other mechanisms may exert compensatory effects, especially in the overexpression study by Qi et al., in which the alterations were longer lasting. Overall, these data support other findings that CRF₂ receptor agonism or overexpression reduces anxiety-like behavior during withdrawal. Nonetheless, throughout the extended amygdala, CRF overexpression has a wide array of effects. For example, another study by Qi et al. showed that CRF overexpression in the BNST reduced dysphoric-like symptoms in rats after mecamylamine-precipitated nicotine withdrawal (Qi et al., 2016). Further research needs to be conducted to more conclusively reveal the role of CRF in regulating nicotine-associated dysphoria.

Stress-induced reinstatement is usually tested in rodent models following a specific period of abstinence from nicotine. Stress is usually induced by footshock or the pharmacological stressor yohimbine. Corticotropin-releasing factor has been shown to mediate footshock-induced reinstatement in nicotine-dependent animals (Plaza-Zabala et al., 2010). Zislis et al. showed that the footshock-induced reinstatement of nicotine seeking decreased after i.c.v. administration of the nonselective CRF receptor antagonist D-Phe CRF₁₂₋₄₁ (Zislis et al., 2007). Bruijnzeel et al. reported similar results with regard to the reinstatement of nicotine seeking using a selective CRF₁ receptor antagonist, but these effects were not seen with a selective CRF₂ receptor antagonist (Bruijnzeel et al., 2009), suggesting that CRF₁ receptors mediate the stress-related reinstatement of nicotine use. Brain regions that are involved in the regulation of stress-induced reinstatement primarily include the extended amygdala (CeA, NAc, and BNST). The BNST is involved in the CRF-mediated stress-induced reinstatement of cocaine seeking (Erb and Stewart, 1999; Vranjkovic et al., 2014). More specifically, a CeA-to-BNST pathway contains CRF that mediates the stress-induced reinstatement of cocaine seeking (Erb et al., 2001). However, remaining unclear is whether such a pathway also mediates the reinstatement of nicotine seeking. The basolateral amygdala has been shown to project to the BNST and regulate CRF-mediated fear- and stress-related behaviors (Walker and Davis, 2008). One possibility is that the basolateral amygdala also plays a role in the stress-induced reinstatement of nicotine seeking. Overall, there is notable consistency in findings that CRF₁ receptor antagonism reduces behaviors that are related to negative affect, including anxiety-like behavior, dysphoria-like behavior, and stress-induced relapse, especially during nicotine withdrawal.

Sex Differences in the Role of CRF in Alcohol and Nicotine Addiction

Nicotine and alcohol are regularly co-abused, but only a few preclinical studies have examined interactions between these two substances (Abreu-Villaca et al., 2008; Larraga et

al., 2017; Ribeiro-Carvalho et al., 2009). Chronic exposure to both alcohol and nicotine activates extrahypothalamic CRF and cholinergic systems. Strong evidence indicates that individuals with AUD are more likely to smoke and *vice versa* (Britt and Bonci, 2013; DiFranza and Guerrero, 1990; Doyon et al., 2013). Leao et al. found that nicotine use facilitated the transition to alcohol dependence (Leao et al., 2015), further establishing the existence of cross-talk between the mechanisms that underlie nicotine- and alcohol-related behaviors.

Alcohol use disorder and tobacco use disorder appear to be differentially regulated in males and females (Agabio et al., 2017; Ceylan-Isik et al., 2010; Pogun et al., 2017). Men tend to have a higher rate of substance abuse (SAMHSA, 2018), but women are more likely to use drugs in the context of stress-related drug use and have more difficulty quitting (Pogun and Yararbas, 2009; Schulte et al., 2009). Men have a greater rate of alcohol intake than women. According to the United States Centers for Disease Control and Prevention, men are twice as likely to binge drink than women, and approximately double the percentage of men *vs.* women met the criteria for AUD in 2016 (Naimi et al., 2003; Nolen-Hoeksema, 2004). However, the number of women with AUD is increasing quickly compared with men (Grant et al., 2017; Slade et al., 2016). Therefore, understanding possible sex differences in the CRF system that contribute to AUD is important. Downstream of the HPA axis, corticosterone levels are higher in female rodents than in males, and more CRF-positive cells are recruited to the PVN in females than in males (Figueiredo et al., 2007; Kudielka and Kirschbaum, 2005; Schreiber and Gilpin, 2018; Silva and Madeira, 2012). Female rodents also exhibit more rewarding effects of alcohol, a phenomenon that has been shown to be hormone dependent. Ovariectomized females do not exhibit such higher rewarding effects of alcohol. Furthermore, estradiol administration has been shown to increase alcohol consumption in female rodents (Ford et al., 2002; Quirarte et al., 2007). Female rats have also been shown to have higher corticosterone levels and exhibit greater sensitivity to the yohimbine-induced reinstatement of alcohol seeking (Bertholomey et al., 2016). These findings corroborate data that show that women are more likely than men to have comorbid AUD and anxiety disorders (Kessler et al., 1997).

With regard to nicotine, the gender gap is closing, in which female rates of smoking, health effects, cessation, and relapse are nearing historical rates that are seen in men. Clinical studies found that the degree to which stress promotes tobacco use is greater in women than in men. Women are more likely to smoke to alleviate negative affective states and regulate mood compared with men (Mykletun et al., 2008; Perkins et al., 1999; Perkins et al., 2013). Female rodents also present greater symptoms and behaviors that are associated with nicotine addiction, including higher nicotine preference, higher anxiety-like behavior, and higher levels of plasma corticosterone and stress-related gene expression. Torres et al. reported sex differences in the role of CRF in nicotine intake, in which CRF enhanced the reinforcing effects of nicotine in females but not in males or ovariectomized females (Uribe et al., 2019). Intact females also exhibited increases in measures of anxiety compared with controls and decreases in CRF₁ receptor, CRF₂ receptor, dopamine D₃ receptor, and estrogen receptor 2 transcripts and an increase in CRF-BP transcripts in the NAc compared with ovariectomized females during nicotine exposure (Torres et al., 2015). Interestingly, estradiol has been shown to increase the rewarding effects of nicotine, which could explain

why females have greater nicotine intake compared with males (Flores et al., 2016). These findings illustrate the importance of ovarian hormones in sex differences in the stress response and nicotine use. However, different phases of the estrous cycle, which causes fluctuations of female hormone levels, did not influence nicotine self-administration in females, in which females still exhibited higher intake than males across the estrous cycle (Perkins et al., 1999). Such sex differences may be related to organizational changes in the brain that occur during adolescence (Vigil et al., 2016). This is relevant to human studies because women are more likely to relapse and maintain nicotine use (Perkins et al., 1999; Smith et al., 2016; Torres and O'Dell, 2016).

Pharmacological manipulations of the CRF system have been employed in both alcohol and nicotine addiction research in an attempt to ameliorate drug-taking and withdrawal-related behaviors. However, surveys of both fields of study show that this approach has been more commonly undertaken in alcohol research than in nicotine research. A potential explanation for this imbalance is that the majority of pharmacological studies of nicotine addiction have targeted nicotinic acetylcholine receptors (nAChRs), the main binding site for nicotine in the brain (Govind et al., 2009). This specific binding is unlike alcohol's mechanism of action, which does not have a specific cellular target but rather causes widespread effects in the brain (Abraham et al., 2017). nAChR composition varies throughout the brain. Pharmacological studies have attempted to activate or block various nAChRs to better understand the role of each receptor variant in addiction (Crooks et al., 2014). Current nicotine replacement therapies, such as varenicline, act as partial agonists at nAChRs to help nicotine users quit (Ebbert et al., 2010). However, these therapies still have not been widely effective. Additional research on pharmacological manipulations of the CRF system to mitigate addiction-related behaviors in nicotine users is needed.

Conclusions

The present review discussed the role of the CRF system in behaviors that are associated with AUD and tobacco use disorder in preclinical models. The majority of brain CRF system-modulated behaviors occur during drug abstinence/withdrawal, including anxiety-like behavior, dysphoria-like behavior, cognitive impairments, and stress-induced relapse. These behavioral effects have been attributed to actions of CRF and Urocortins on the action of CRF₁ and CRF₂ receptors within a distributed network of brain regions, including the PFC, PVN, CeA, BNST, VTA, and IPN. These studies indicate that the recruitment of a distributed brain CRF stress system may provide redundant circuits that promote negative affective states during alcohol and nicotine withdrawal. Further studies are needed to identify specific manipulations of these circuits that can decrease alcohol and nicotine use while maintaining a focus on sexually dimorphic stress-related systems in SUDs.

Acknowledgements

This work was supported by National Institutes of Health grants DA044451, DA043799, DA047113, AA006420, AA020608, AA022977, AA027301, and AA007456, Tobacco-Related Disease Research Program grant 27IR-0047, and the Pearson Center for Alcoholism and Addiction Research. The authors thank Michael Arends for proofreading the manuscript.

References

- Abraham KP, Salinas AG, Lovinger DM, 2017 Alcohol and the Brain: Neuronal Molecular Targets, Synapses, and Circuits. *Neuron*. 96, 1223–1238. [PubMed: 29268093]
- Abreu-Villaca Y, et al., 2008 Combined exposure to nicotine and ethanol in adolescent mice differentially affects anxiety levels during exposure, short-term, and long-term withdrawal. *Neuropsychopharmacology*. 33, 599–610. [PubMed: 17460612]
- Agabio R, et al., 2017 Sex Differences in Alcohol Use Disorder. *Curr Med Chem*. 24, 2661–2670. [PubMed: 27915987]
- Albrechet-Souza L, et al., 2015 Corticotropin Releasing Factor Binding Protein and CRF2 Receptors in the Ventral Tegmental Area: Modulation of Ethanol Binge Drinking in C57BL/6J Mice. *Alcohol Clin Exp Res*. 39, 1609–18. [PubMed: 26247973]
- Alheid GF, Heimer L, 1988 New perspectives in basal forebrain organization of special relevance for neuropsychiatric disorders: the striatopallidal, amygdaloid, and corticopetal components of substantia innominata. *Neuroscience*. 27, 1–39. [PubMed: 3059226]
- Andreasen JT, et al., 2008 Antidepressant-like effects of nicotinic acetylcholine receptor antagonists, but not agonists, in the mouse forced swim and mouse tail suspension tests. *Journal of Psychopharmacology*. 23, 797–804. [PubMed: 18583432]
- Anthony TE, et al., 2014 Control of stress-induced persistent anxiety by an extra-amygdala septohypothalamic circuit. *Cell*. 156, 522–36. [PubMed: 24485458]
- Arborelius L, et al., 1999 The role of corticotropin-releasing factor in depression and anxiety disorders. *J Endocrinol*. 160, 1–12. [PubMed: 9854171]
- Avegno EM, et al., 2018 Central Amygdala Circuits Mediate Hyperalgesia in Alcohol-Dependent Rats. *The Journal of Neuroscience*. 38, 7761–7773. [PubMed: 30054393]
- Ayanwuyi LO, et al., 2013 Role of a genetic polymorphism in the corticotropin-releasing factor receptor 1 gene in alcohol drinking and seeking behaviors of marchigian sardinian alcohol-preferring rats. *Frontiers in psychiatry*. 4, 23–23. [PubMed: 23630503]
- Bagosi Z, et al., 2016 Selective CRF2 receptor agonists ameliorate the anxiety- and depression-like state developed during chronic nicotine treatment and consequent acute withdrawal in mice. *Brain Research*. 1652, 21–29. [PubMed: 27693397]
- Baiamonte BA, et al., 2014 Nicotine dependence produces hyperalgesia: role of corticotropin-releasing factor-1 receptors (CRF1Rs) in the central amygdala (CeA). *Neuropharmacology*. 77, 217–23. [PubMed: 24107576]
- Baldwin HA, et al., 1991 CRF antagonist reverses the “anxiogenic” response to ethanol withdrawal in the rat. *Psychopharmacology*. 103, 227–232. [PubMed: 2027923]
- Bale TL, et al., 2000 Mice deficient for corticotropin-releasing hormone receptor-2 display anxiety-like behaviour and are hypersensitive to stress. *Nat Genet*. 24, 410–4. [PubMed: 10742108]
- Bale TL, et al., 2002 Mice deficient for both corticotropin-releasing factor receptor 1 (CRFR1) and CRFR2 have an impaired stress response and display sexually dichotomous anxiety-like behavior. *J Neurosci*. 22, 193–9. [PubMed: 11756502]
- Bale TL, Vale WW, 2004 CRF AND CRF R ECEPTORS : Role in Stress Responsivity and Other Behaviors. 44, 525–557.
- Balerio GN, Aso E, Maldonado R, 2005 Involvement of the opioid system in the effects induced by nicotine on anxiety-like behaviour in mice. *Psychopharmacology (Berl)*. 181, 260–9. [PubMed: 15778877]
- Barr CS, et al., 2009 Functional CRH variation increases stress-induced alcohol consumption in primates. *Proc Natl Acad Sci U S A*. 106, 14593–8. [PubMed: 19706546]
- Becker HC, 2008 Alcohol dependence, withdrawal, and relapse. *Alcohol Res Health*. 31, 348–61. [PubMed: 23584009]
- Behan DP, et al., 1995 Corticotropin releasing factor (CRF) binding protein: a novel regulator of CRF and related peptides. *Front Neuroendocrinol*. 16, 362–82. [PubMed: 8557170]

- Bell SM, et al., 1998 Effects of third intracerebroventricular injections of corticotropin-releasing factor (CRF) on ethanol drinking and food intake. *Psychopharmacology (Berl)*. 139, 128–35. [PubMed: 9768550]
- Bertholomey ML, Nagarajan V, Torregrossa MM, 2016 Sex differences in reinstatement of alcohol seeking in response to cues and yohimbine in rats with and without a history of adolescent corticosterone exposure. *Psychopharmacology (Berl)*. 233, 2277–87. [PubMed: 27048157]
- Bittencourt JC, Sawchenko PE, 2000 Do centrally administered neuropeptides access cognate receptors?: an analysis in the central corticotropin-releasing factor system. *J Neurosci*. 20, 1142–56. [PubMed: 10648719]
- Blaine SK, et al., 2016 Alcohol Effects on Stress Pathways: Impact on Craving and Relapse Risk. *Can J Psychiatry*. 61, 145–53. [PubMed: 27254089]
- Bradbury MJ, et al., 2000 Modulation of urocortin-induced hypophagia and weight loss by corticotropin-releasing factor receptor 1 deficiency in mice. *Endocrinology*. 141, 2715–24. [PubMed: 10919255]
- Breese GR, et al., 2005 Stress enhancement of craving during sobriety: a risk for relapse. *Alcohol Clin Exp Res*. 29, 185–95. [PubMed: 15714042]
- Breese GR, Knapp DJ, 2016 Persistent adaptation by chronic alcohol is facilitated by neuroimmune activation linked to stress and CRF. *Alcohol*. 52, 9–23. [PubMed: 27139233]
- Britt JP, Bonci A, 2013 Alcohol and tobacco: how smoking may promote excessive drinking. *Neuron*. 79, 406–7. [PubMed: 23931990]
- Britton KT, et al., 1986a Activating and ‘anxiogenic’ effects of corticotropin releasing factor are not inhibited by blockade of the pituitary-adrenal system with dexamethasone. *Life Sci*. 39, 1281–6. [PubMed: 3489874]
- Britton KT, et al., 1986b Corticotropin releasing factor (CRF) receptor antagonist blocks activating and ‘anxiogenic’ actions of CRF in the rat. *Brain Res*. 369, 303–6. [PubMed: 3008937]
- Bruijnzeel AW, Gold MS, 2005 The role of corticotropin-releasing factor-like peptides in cannabis, nicotine, and alcohol dependence. *Brain Res Brain Res Rev*. 49, 505–28. [PubMed: 16269317]
- Bruijnzeel AW, et al., 2007 Antagonism of CRF receptors prevents the deficit in brain reward function associated with precipitated nicotine withdrawal in rats. *Neuropsychopharmacology*. 32, 955–63. [PubMed: 16943772]
- Bruijnzeel AW, Prado M, Isaac S, 2009 Corticotropin-releasing factor-1 receptor activation mediates nicotine withdrawal-induced deficit in brain reward function and stress-induced relapse. *Biol Psychiatry*. 66, 110–7. [PubMed: 19217073]
- Bruijnzeel AW, et al., 2010 Corticotropin-releasing factor mediates the dysphoria-like state associated with alcohol withdrawal in rats. *Behavioural Brain Research*. 210, 288–291. [PubMed: 20193713]
- Bruijnzeel AW, 2012a Tobacco addiction and the dysregulation of brain stress systems. *Neuroscience & Biobehavioral Reviews*. 36, 1418–1441. [PubMed: 22405889]
- Bruijnzeel AW, 2012b Tobacco addiction and the dysregulation of brain stress systems. *Neurosci Biobehav Rev*. 36, 1418–41. [PubMed: 22405889]
- Bryce CA, Floresco SB, 2016 Perturbations in Effort-Related Decision-Making Driven by Acute Stress and Corticotropin-Releasing Factor. *Neuropsychopharmacology*. 41, 2147–59. [PubMed: 26830960]
- Burrows HL, et al., 1998 Excess corticotropin releasing hormone-binding protein in the hypothalamic-pituitary-adrenal axis in transgenic mice. *J Clin Invest*. 101, 1439–47. [PubMed: 9525987]
- Ceylan-Isik AF, McBride SM, Ren J, 2010 Sex difference in alcoholism: who is at a greater risk for development of alcoholic complication? *Life Sci*. 87, 133–8. [PubMed: 20598716]
- Chu K, et al., 2007 Dependence-induced increases in ethanol self-administration in mice are blocked by the CRF1 receptor antagonist antalarmin and by CRF1 receptor knockout. *Pharmacol Biochem Behav*. 86, 813–21. [PubMed: 17482248]
- Cohen A, Koob GF, George O, 2012 Robust escalation of nicotine intake with extended access to nicotine self-administration and intermittent periods of abstinence. *Neuropsychopharmacology*. 37, 2153–60. [PubMed: 22549121]
- Cohen A, George O, 2013 Animal models of nicotine exposure: relevance to second-hand smoking, electronic cigarette use, and compulsive smoking. *Front Psychiatry*. 4, 41. [PubMed: 23761766]

- Cohen A, et al., 2015 Extended access to nicotine leads to a CRF1 receptor dependent increase in anxiety-like behavior and hyperalgesia in rats. *Addict Biol.* 20, 56–68. [PubMed: 23869743]
- Coste SC, et al., 2000 Abnormal adaptations to stress and impaired cardiovascular function in mice lacking corticotropin-releasing hormone receptor-2. *Nat Genet.* 24, 403–9. [PubMed: 10742107]
- Crooks PA, Bardo MT, Dwoskin LP, 2014 Nicotinic receptor antagonists as treatments for nicotine abuse. *Adv Pharmacol.* 69, 513–51. [PubMed: 24484986]
- Cullen MJ, et al., 2001 Urocortin, corticotropin releasing factor-2 receptors and energy balance. *Endocrinology.* 142, 992–9. [PubMed: 11181511]
- Cummings S, et al., 1983 Corticotropin-releasing factor immunoreactivity is widely distributed within the central nervous system of the rat: an immunohistochemical study. *J Neurosci.* 3, 1355–68. [PubMed: 6345725]
- Dabrowska J, et al., 2016 Targeting Corticotropin-Releasing Factor Projections from the Oval Nucleus of the Bed Nucleus of the Stria Terminalis Using Cell-Type Specific Neuronal Tracing Studies in Mouse and Rat Brain. *J Neuroendocrinol.* 28.
- Dautzenberg FM, Hauger RL, 2002 The CRF peptide family and their receptors: yet more partners discovered. *Trends in Pharmacological Sciences.* 23, 71–77. [PubMed: 11830263]
- Davis M, et al., 2010 Phasic vs sustained fear in rats and humans: role of the extended amygdala in fear vs anxiety. *Neuropsychopharmacology.* 35, 105–35. [PubMed: 19693004]
- de Guglielmo G, et al., 2016 Recruitment of a Neuronal Ensemble in the Central Nucleus of the Amygdala Is Required for Alcohol Dependence. *The Journal of Neuroscience.* 36, 9446–9453. [PubMed: 27605618]
- de Guglielmo G, et al., 2019 Inactivation of a CRF-dependent amygdalofugal pathway reverses addiction-like behaviors in alcohol-dependent rats. *Nature Communications.* 10, 1238.
- Devilbiss DM, Spencer RC, Berridge CW, 2016 Stress Degrades Prefrontal Cortex Neuronal Coding of Goal-Directed Behavior. *Cerebral Cortex.* 27, 2970–2983.
- DiFranza JR, Guerrero MP, 1990 Alcoholism and smoking. *J Stud Alcohol.* 51, 130–5. [PubMed: 2308350]
- Doyon WM, et al., 2013 Potential substrates for nicotine and alcohol interactions: a focus on the mesocorticolimbic dopamine system. *Biochem Pharmacol.* 86, 1181–93. [PubMed: 23876345]
- Dunn AJ, Berridge CW, 1990 Physiological and behavioral responses to corticotropin-releasing factor administration: is CRF a mediator of anxiety or stress responses? *Brain Res Brain Res Rev.* 15, 71–100. [PubMed: 1980834]
- Ebbert JO, et al., 2010 Varenicline for smoking cessation: efficacy, safety, and treatment recommendations. *Patient Prefer Adherence.* 4, 355–62. [PubMed: 21049087]
- Erb S, Stewart J, 1999 A role for the bed nucleus of the stria terminalis, but not the amygdala, in the effects of corticotropin-releasing factor on stress-induced reinstatement of cocaine seeking. *J Neurosci.* 19, RC35. [PubMed: 10516337]
- Erb S, et al., 2001 A role for the CRF-containing pathway from central nucleus of the amygdala to bed nucleus of the stria terminalis in the stress-induced reinstatement of cocaine seeking in rats. *Psychopharmacology (Berl).* 158, 360–5. [PubMed: 11797056]
- Figueiredo HF, et al., 2007 Estrogen potentiates adrenocortical responses to stress in female rats. *Am J Physiol Endocrinol Metab.* 292, E1173–82. [PubMed: 17179393]
- File SE, Kenny PJ, Ouagazzal AM, 1998 Bimodal modulation by nicotine of anxiety in the social interaction test: role of the dorsal hippocampus. *Behav Neurosci.* 112, 1423–9. [PubMed: 9926824]
- Finn DA, et al., 2007 Increased drinking during withdrawal from intermittent ethanol exposure is blocked by the CRF receptor antagonist D-Phe-CRF(12–41). *Alcohol Clin Exp Res.* 31, 939–49. [PubMed: 17403068]
- Flores RJ, et al., 2016 Estradiol promotes the rewarding effects of nicotine in female rats. *Behav Brain Res.* 307, 258–63. [PubMed: 27059334]
- Ford MM, Eldridge JC, Samson HH, 2002 Ethanol consumption in the female Long-Evans rat: a modulatory role of estradiol. *Alcohol.* 26, 103–13. [PubMed: 12007585]

- Funk CK, et al., 2006 Corticotropin-Releasing Factor within the Central Nucleus of the Amygdala Mediates Enhanced Ethanol Self-Administration in Withdrawn, Ethanol-Dependent Rats. *Journal of Neuroscience*. 26, 11324–11332. [PubMed: 17079660]
- Funk CK, Koob GF, 2007 A CRF(2) agonist administered into the central nucleus of the amygdala decreases ethanol self-administration in ethanol-dependent rats. *Brain Res*. 1155, 172–8. [PubMed: 17512918]
- Funk CK, et al., 2007 Corticotropin-releasing factor 1 antagonists selectively reduce ethanol self-administration in ethanol-dependent rats. *Biol Psychiatry*. 61, 78–86. [PubMed: 16876134]
- Fuzesi T, et al., 2016 Hypothalamic CRH neurons orchestrate complex behaviours after stress. *Nat Commun*. 7, 11937. [PubMed: 27306314]
- Gammie SC, Seasholtz AF, Stevenson SA, 2008 Deletion of corticotropin-releasing factor binding protein selectively impairs maternal, but not intermale aggression. *Neuroscience*. 157, 502–12. [PubMed: 18929624]
- Gehlert DR, et al., 2007 3-(4-Chloro-2-morpholin-4-yl-thiazol-5-yl)-8-(1-ethylpropyl)-2,6-dimethylimidazo [1,2-b]pyridazine: a novel brain-penetrant, orally available corticotropin-releasing factor receptor 1 antagonist with efficacy in animal models of alcoholism. *J Neurosci*. 27, 2718–26. [PubMed: 17344409]
- George O, et al., 2007 CRF CRF1 system activation mediates withdrawal-induced increases in nicotine self-administration in nicotine-dependent rats. *Proceedings of the National Academy of Sciences*. 104, 17198–17203.
- George O, et al., 2012 Recruitment of medial prefrontal cortex neurons during alcohol withdrawal predicts cognitive impairment and excessive alcohol drinking. *Proceedings of the National Academy of Sciences*. 109, 18156–18161.
- Giardino WJ, Ryabinin AE, 2013 CRF1 receptor signaling regulates food and fluid intake in the drinking-in-the-dark model of binge alcohol consumption. *Alcohol Clin Exp Res*. 37, 1161–70. [PubMed: 23398267]
- Gilpin NW, Richardson HN, Koob GF, 2008 Effects of CRF1-receptor and opioid-receptor antagonists on dependence-induced increases in alcohol drinking by alcohol-preferring (P) rats. *Alcohol Clin Exp Res*. 32, 1535–42. [PubMed: 18631323]
- Gilpin NW, 2012 Corticotropin-releasing factor (CRF) and neuropeptide Y (NPY): effects on inhibitory transmission in central amygdala, and anxiety- & alcohol-related behaviors. *Alcohol*. 46, 329–37. [PubMed: 22560367]
- Gilpin NW, et al., 2014 Nicotine vapor inhalation escalates nicotine self-administration. *Addict Biol*. 19, 587–92. [PubMed: 23240929]
- Govind AP, Vezina P, Green WN, 2009 Nicotine-induced upregulation of nicotinic receptors: underlying mechanisms and relevance to nicotine addiction. *Biochem Pharmacol*. 78, 756–65. [PubMed: 19540212]
- Grant BF, et al., 2017 Prevalence of 12-Month Alcohol Use, High-Risk Drinking, and DSM-IV Alcohol Use Disorder in the United States, 2001–2002 to 2012–2013: Results From the National Epidemiologic Survey on Alcohol and Related Conditions. *JAMA Psychiatry*. 74, 911–923. [PubMed: 28793133]
- Griebel G, 2002 4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]5-methyl-N-(2-propynyl)-1, 3-thiazol-2-amine Hydrochloride (SSR125543A), a Potent and Selective Corticotropin-Releasing Factor1 Receptor Antagonist. II. Characterization in Rodent Models of Stress-Related Disorders. 301, 333–345.
- Grieder TE, et al., 2014 VTA CRF neurons mediate the aversive effects of nicotine withdrawal and promote intake escalation. *Nat Neurosci*. 17, 1751–8. [PubMed: 25402857]
- Groenink L, et al., 2002 HPA axis dysregulation in mice overexpressing corticotropin releasing hormone. *Biol Psychiatry*. 51, 875–81. [PubMed: 12022960]
- Haass-Koffler CL, Bartlett SE, 2012 Stress and addiction: contribution of the corticotropin releasing factor (CRF) system in neuroplasticity. *Front Mol Neurosci*. 5, 91. [PubMed: 22973190]
- Haass-Koffler CL, 2018 The corticotropin releasing factor binding protein: A strange case of Dr. Jekyll and Mr. Hyde in the stress system? *Alcohol*. 72, 3–8. [PubMed: 29510883]

- Hansson AC, et al., 2006 Variation at the rat *Crhr1* locus and sensitivity to relapse into alcohol seeking induced by environmental stress. *Proc Natl Acad Sci U S A.* 103, 15236–41. [PubMed: 17015825]
- Hansson AC, et al., 2007 Region-specific down-regulation of *Crhr1* gene expression in alcohol-preferring msP rats following ad lib access to alcohol. *Addict Biol.* 12, 30–4. [PubMed: 17407495]
- Hauger RL, et al., 2006 Corticotropin releasing factor (CRF) receptor signaling in the central nervous system: new molecular targets. *CNS Neurol Disord Drug Targets.* 5, 453–79. [PubMed: 16918397]
- Heilig M, et al., 2010 Acute withdrawal, protracted abstinence and negative affect in alcoholism: are they linked? *Addict Biol.* 15, 169–84. [PubMed: 20148778]
- Heimer L, Alheid GF, 1991 Piecing together the puzzle of basal forebrain anatomy. *Adv Exp Med Biol.* 295, 1–42.
- Heinrichs SC, et al., 1992 Corticotropin-releasing factor antagonist reduces emotionality in socially defeated rats via direct neurotropic action. *Brain Res.* 581, 190–7. [PubMed: 1327398]
- Heinrichs SC, et al., 1996 Corticotropin-releasing factor-binding protein ligand inhibitor blunts excessive weight gain in genetically obese Zucker rats and rats during nicotine withdrawal. *Proc Natl Acad Sci U S A.* 93, 15475–80. [PubMed: 8986836]
- Henckens M, et al., 2017 CRF receptor type 2 neurons in the posterior bed nucleus of the stria terminalis critically contribute to stress recovery. *Mol Psychiatry.* 22, 1691–1700. [PubMed: 27550842]
- Henckens MJ, Deussing JM, Chen A, 2016 Region-specific roles of the corticotropin-releasing factor-urocortin system in stress. *Nat Rev Neurosci.* 17, 636–51. [PubMed: 27586075]
- Herman JP, Cullinan WE, Watson SJ, 1994 Involvement of the bed nucleus of the stria terminalis in tonic regulation of paraventricular hypothalamic CRH and AVP mRNA expression. *J Neuroendocrinol.* 6, 433–42. [PubMed: 7987374]
- Herman JP, et al., 2016 Regulation of the Hypothalamic-Pituitary-Adrenocortical Stress Response. *Compr Physiol.* 6, 603–21. [PubMed: 27065163]
- Huang MM, et al., 2010 Corticotropin-releasing factor (CRF) sensitization of ethanol withdrawal-induced anxiety-like behavior is brain site specific and mediated by CRF-1 receptors: relation to stress-induced sensitization. *J Pharmacol Exp Ther.* 332, 298–307. [PubMed: 19843974]
- Hughes JR, et al., 2004 Concordance of different measures of nicotine dependence: two pilot studies. *Addict Behav.* 29, 1527–39. [PubMed: 15451122]
- Hupalo S, Berridge CW, 2016 Working Memory Impairing Actions of Corticotropin-Releasing Factor (CRF) Neurotransmission in the Prefrontal Cortex. *Neuropsychopharmacology.* 41, 2733–40. [PubMed: 27272767]
- Hupalo S, et al., 2019 Prefrontal Corticotropin-Releasing Factor (CRF) Neurons Act Locally to Modulate Frontostriatal Cognition and Circuit Function. *J Neurosci.* 39, 2080–2090. [PubMed: 30651328]
- Hwa LS, Debold JF, Miczek KA, 2013 Alcohol in excess: CRF(1) receptors in the rat and mouse VTA and DRN. *Psychopharmacology (Berl).* 225, 313–27. [PubMed: 22885872]
- Hwa LS, et al., 2016 Social stress-escalated intermittent alcohol drinking: modulation by CRF-R1 in the ventral tegmental area and accumbal dopamine in mice. *Psychopharmacology (Berl).* 233, 681–90. [PubMed: 26576941]
- Jarvis MJ, 2004 Why people smoke. *BMJ.* 328, 277–9. [PubMed: 14751901]
- Jiang Z, Rajamanickam S, Justice NJ, 2018a Local Corticotropin-Releasing Factor Signaling in the Hypothalamic Paraventricular Nucleus. *The Journal of Neuroscience.* 38, 1874. [PubMed: 29352046]
- Jiang Z, Rajamanickam S, Justice NJ, 2018b Local Corticotropin-Releasing Factor Signaling in the Hypothalamic Paraventricular Nucleus. *J Neurosci.* 38, 1874–1890. [PubMed: 29352046]
- Karolyi IJ, et al., 1999 Altered anxiety and weight gain in corticotropin-releasing hormone-binding protein-deficient mice. *Proc Natl Acad Sci U S A.* 96, 11595–600. [PubMed: 10500222]
- Kaur S, et al., 2012 Corticotropin-releasing factor acting on corticotropin-releasing factor receptor type 1 is critical for binge alcohol drinking in mice. *Alcohol Clin Exp Res.* 36, 369–76. [PubMed: 21895713]

- Keen-Rhinehart E, et al., 2009 Continuous expression of corticotropin-releasing factor in the central nucleus of the amygdala emulates the dysregulation of the stress and reproductive axes. *Mol Psychiatry*. 14, 37–50. [PubMed: 18698320]
- Kessler RC, et al., 1997 Lifetime co-occurrence of DSM-III-R alcohol abuse and dependence with other psychiatric disorders in the National Comorbidity Survey. *Arch Gen Psychiatry*. 54, 313–21. [PubMed: 9107147]
- Ketchesin KD, Seasholtz AF, 2015 Novel Roles for CRF-Binding Protein and CRF Receptor 2 in Binge Drinking. *Alcohol Clin Exp Res*. 39, 2296–8. [PubMed: 26509254]
- Ketchesin KD, Stinnett GS, Seasholtz AF, 2017 Corticotropin-releasing hormone-binding protein and stress: from invertebrates to humans. *Stress*. 20, 449–464. [PubMed: 28436309]
- Kim EH, Ryu DH, Hwang S, 2011 The expression of corticotropin-releasing factor and its receptors in the spinal cord and dorsal root ganglion in a rat model of neuropathic pain. *Anat Cell Biol*. 44, 60–8. [PubMed: 21519550]
- Kim J, et al., 2019 Rapid, biphasic CRF neuronal responses encode positive and negative valence. *Nat Neurosci*. 22, 576–585. [PubMed: 30833699]
- Kimbrough A, et al., 2017 CRF1 Receptor-Dependent Increases in Irritability-Like Behavior During Abstinence from Chronic Intermittent Ethanol Vapor Exposure. *Alcoholism: Clinical and Experimental Research*. 41, 1886–1895.
- Kishimoto T, et al., 2000 Deletion of *crhr2* reveals an anxiolytic role for corticotropin-releasing hormone receptor-2. *Nat Genet*. 24, 415–9. [PubMed: 10742109]
- Klenowski PM, 2018 Emerging role for the medial prefrontal cortex in alcohol-seeking behaviors. *Addictive Behaviors*. 77, 102–106. [PubMed: 28992574]
- Knapp DJ, et al., 2004 SB242084, flumazenil, and CRA1000 block ethanol withdrawal-induced anxiety in rats. *Alcohol*. 32, 101–11. [PubMed: 15163561]
- Koob GF, Heinrichs SC, 1999 A role for corticotropin releasing factor and urocortin in behavioral responses to stressors. *Brain Res*. 848, 141–52. [PubMed: 10612706]
- Koob GF, 2008 A Role for Brain Stress Systems in Addiction. *Neuron*. 59, 11–34. [PubMed: 18614026]
- Koob GF, 2009 Brain stress systems in the amygdala and addiction. *Brain Research*. 1293, 61–75. [PubMed: 19332030]
- Koob GF, 2010 The role of CRF and CRF-related peptides in the dark side of addiction. *Brain Res*. 1314, 3–14. [PubMed: 19912996]
- Korosi A, et al., 2006 Distribution and expression of CRF receptor 1 and 2 mRNAs in the CRF over-expressing mouse brain. *Brain Res*. 1072, 46–54. [PubMed: 16423327]
- Krettek JE, Price JL, 1978 Amygdaloid projections to subcortical structures within the basal forebrain and brainstem in the rat and cat. 178, 225–253.
- Kudielka BM, Kirschbaum C, 2005 Sex differences in HPA axis responses to stress: a review. *Biol Psychol*. 69, 113–32. [PubMed: 15740829]
- Kwako LE, et al., 2015 The corticotropin releasing hormone-1 (CRH1) receptor antagonist pexacerfont in alcohol dependence: a randomized controlled experimental medicine study. *Neuropsychopharmacology*. 40, 1053–63. [PubMed: 25409596]
- Kwako LE, Koob GF, 2017 Neuroclinical Framework for the Role of Stress in Addiction. *Chronic Stress (Thousand Oaks)*. 1.
- Land BB, et al., 2008 The dysphoric component of stress is encoded by activation of the dynorphin kappa-opioid system. *J Neurosci*. 28, 407–14. [PubMed: 18184783]
- Larraga A, Belluzzi JD, Leslie FM, 2017 Nicotine Increases Alcohol Intake in Adolescent Male Rats. *Front Behav Neurosci*. 11, 25. [PubMed: 28275339]
- Le AD, et al., 2000 The role of corticotropin-releasing factor in stress-induced relapse to alcohol-seeking behavior in rats. *Psychopharmacology (Berl)*. 150, 317–24. [PubMed: 10923760]
- Le AD, et al., 2002 The role of corticotropin-releasing factor in the median raphe nucleus in relapse to alcohol. *J Neurosci*. 22, 7844–9. [PubMed: 12223536]
- Leao RM, et al., 2015 Chronic nicotine activates stress/reward-related brain regions and facilitates the transition to compulsive alcohol drinking. *J Neurosci*. 35, 6241–53. [PubMed: 25878294]

- Liu X, Weiss F, 2003 Stimulus conditioned to foot-shock stress reinstates alcohol-seeking behavior in an animal model of relapse. *Psychopharmacology (Berl)*. 168, 184–191. [PubMed: 12447607]
- Lodge DJ, Lawrence AJ, 2003 The CRF1 receptor antagonist antalarmin reduces volitional ethanol consumption in isolation-reared fawn-hooded rats. *Neuroscience*. 117, 243–7. [PubMed: 12614667]
- Logrip ML, et al., 2013 Adolescent alcohol exposure alters the rat adult hypothalamic-pituitary-adrenal axis responsiveness in a sex-specific manner. *Neuroscience*. 235, 174–86. [PubMed: 23337533]
- Lovejoy DA, et al., 1998 Ectopic expression of the CRF-binding protein: minor impact on HPA axis regulation but induction of sexually dimorphic weight gain. *J Neuroendocrinol*. 10, 483–91. [PubMed: 9700675]
- Lowery EG, et al., 2008 The CRF-1 receptor antagonist, CP-154,526, attenuates stress-induced increases in ethanol consumption by BALB/cJ mice. *Alcohol Clin Exp Res*. 32, 240–8. [PubMed: 18162074]
- Lowery EG, Thiele TE, 2010 Pre-clinical evidence that corticotropin-releasing factor (CRF) receptor antagonists are promising targets for pharmacological treatment of alcoholism. *CNS Neurol Disord Drug Targets*. 9, 77–86. [PubMed: 20201818]
- Lowery-Gionta EG, et al., 2012 Corticotropin releasing factor signaling in the central amygdala is recruited during binge-like ethanol consumption in C57BL/6J mice. *J Neurosci*. 32, 3405–13. [PubMed: 22399763]
- Ludwig AM, Wikler A, 1974 “Craving” and relapse to drink. *Q J Stud Alcohol*. 35, 108–30. [PubMed: 4827273]
- Marcinkiewicz CA, et al., 2009 Corticotropin-Releasing Factor Within the Central Nucleus of the Amygdala and the Nucleus Accumbens Shell Mediates the Negative Affective State of Nicotine Withdrawal in Rats. *Neuropsychopharmacology*. 34, 1743–1752. [PubMed: 19145226]
- Marinelli PW, et al., 2007 The CRF1 receptor antagonist antalarmin attenuates yohimbine-induced increases in operant alcohol self-administration and reinstatement of alcohol seeking in rats. *Psychopharmacology (Berl)*. 195, 345–55. [PubMed: 17705061]
- Miguel TT, Gomes KS, Nunes-de-Souza RL, 2014 Tonic modulation of anxiety-like behavior by corticotropin-releasing factor (CRF) type 1 receptor (CRF1) within the medial prefrontal cortex (mPFC) in male mice: role of protein kinase A (PKA). *Horm Behav*. 66, 247–56. [PubMed: 24848364]
- Molander A, et al., 2012 Brain-specific inactivation of the *Crhr1* gene inhibits post-dependent and stress-induced alcohol intake, but does not affect relapse-like drinking. *Neuropsychopharmacology*. 37, 1047–56. [PubMed: 22113086]
- Molas S, et al., 2017 Anxiety and Nicotine Dependence: Emerging Role of the Habenulo-Interpeduncular Axis. *Trends Pharmacol Sci*. 38, 169–180. [PubMed: 27890353]
- Morin SM, et al., 1999 Differential distribution of urocortin- and corticotropin-releasing factor-like immunoreactivities in the rat brain. *Neuroscience*. 92, 281–91. [PubMed: 10392850]
- Muglia L, et al., 1995 Corticotropin-releasing hormone deficiency reveals major fetal but not adult glucocorticoid need. *Nature*. 373, 427–32. [PubMed: 7830793]
- Mykletun A, et al., 2008 Smoking in relation to anxiety and depression: Evidence from a large population survey: The HUNT study. *European Psychiatry*. 23, 77–84. [PubMed: 18082377]
- Naimi TS, et al., 2003 Binge drinking among US adults. *JAMA*. 289, 70–5. [PubMed: 12503979]
- Neufeld-Cohen A, et al., 2010a Urocortin-1 and -2 double-deficient mice show robust anxiolytic phenotype and modified serotonergic activity in anxiety circuits. *Mol Psychiatry*. 15, 426–41, 339. [PubMed: 19884890]
- Neufeld-Cohen A, et al., 2010b A triple urocortin knockout mouse model reveals an essential role for urocortins in stress recovery. *Proc Natl Acad Sci U S A*. 107, 19020–5. [PubMed: 20937857]
- Neufeld-Cohen A, et al., 2012 Chronic activation of corticotropin-releasing factor type 2 receptors reveals a key role for 5-HT1A receptor responsiveness in mediating behavioral and serotonergic responses to stressful challenge. *Biol Psychiatry*. 72, 437–47. [PubMed: 22704666]
- Nolen-Hoeksema S, 2004 Gender differences in risk factors and consequences for alcohol use and problems. *Clin Psychol Rev*. 24, 981–1010. [PubMed: 15533281]

- O'Callaghan MJ, et al., 2005 The hypothalamopituitary-adrenal axis and alcohol preference. *Brain Res Bull.* 68, 171–8. [PubMed: 16325017]
- Olive MF, et al., 2002 Elevated extracellular CRF levels in the bed nucleus of the stria terminalis during ethanol withdrawal and reduction by subsequent ethanol intake. *Pharmacology Biochemistry and Behavior.* 72, 213–220.
- Overstreet DH, Keeney A, Hogg S, 2004a Antidepressant effects of citalopram and CRF receptor antagonist CP-154,526 in a rat model of depression. *Eur J Pharmacol.* 492, 195–201. [PubMed: 15178365]
- Overstreet DH, Knapp DJ, Breese GR, 2004b Modulation of multiple ethanol withdrawal-induced anxiety-like behavior by CRF and CRF1 receptors. *Pharmacol Biochem Behav.* 77, 405–13. [PubMed: 14751471]
- Palmer AA, et al., 2004 Corticotropin-releasing factor overexpression decreases ethanol drinking and increases sensitivity to the sedative effects of ethanol. *Psychopharmacology (Berl).* 176, 386–97. [PubMed: 15138758]
- Pastor R, et al., 2008 Corticotropin-releasing factor-1 receptor involvement in behavioral neuroadaptation to ethanol: a urocortin1-independent mechanism. *Proc Natl Acad Sci U S A.* 105, 9070–5. [PubMed: 18591672]
- Pastor R, et al., 2011 Ethanol concentration-dependent effects and the role of stress on ethanol drinking in corticotropin-releasing factor type 1 and double type 1 and 2 receptor knockout mice. *Psychopharmacology (Berl).* 218, 169–77. [PubMed: 21487655]
- Pelleymounter MA, et al., 2000 Role of corticotropin-releasing factor (CRF) receptors in the anorexic syndrome induced by CRF. *J Pharmacol Exp Ther.* 293, 799–806. [PubMed: 10869378]
- Perkins K, Donny E, Caggiula A, 1999 Sex differences in nicotine effects and self-administration: Review of human and animal evidence. 1, 301–315.
- Perkins KA, et al., 2013 Negative mood effects on craving to smoke in women versus men. *Addictive Behaviors.* 38, 1527–1531. [PubMed: 22726579]
- Perrin M, et al., 1995 Identification of a second corticotropin-releasing factor receptor gene and characterization of a cDNA expressed in heart. *Proc Natl Acad Sci U S A.* 92, 2969–73. [PubMed: 7708757]
- Piazza PV, et al., 1993 Corticosterone in the range of stress-induced levels possesses reinforcing properties: implications for sensation-seeking behaviors. *Proc Natl Acad Sci U S A.* 90, 11738–42. [PubMed: 8265619]
- Piazza PV, Le Moal M, 1997 Glucocorticoids as a biological substrate of reward: physiological and pathophysiological implications. *Brain Res Brain Res Rev.* 25, 359–72. [PubMed: 9495563]
- Pitklnen ADGA, 2000 The Distribution of GABAergic Cells, Fibers, and Terminals in the Monkey Amygdaloid Complex: An Immunohistochemical and in situ Hybridization Study *Neuroscience* 14, 2200–2224.
- Plaza-Zabala A, et al., 2010 Hypocretins Regulate the Anxiogenic-Like Effects of Nicotine and Induce Reinstatement of Nicotine-Seeking Behavior. *The Journal of Neuroscience.* 30, 2300. [PubMed: 20147556]
- Pleil KE, et al., 2015 NPY signaling inhibits extended amygdala CRF neurons to suppress binge alcohol drinking. *Nat Neurosci.* 18, 545–52. [PubMed: 25751534]
- Pogun S, Yararbas G, 2009 Sex differences in nicotine action. *Handb Exp Pharmacol.* 261–91.
- Pogun S, et al., 2017 Sex differences in nicotine preference. *J Neurosci Res.* 95, 148–162. [PubMed: 27870459]
- Pomrenze MB, et al., 2015 A Transgenic Rat for Investigating the Anatomy and Function of Corticotropin Releasing Factor Circuits. *Front Neurosci.* 9, 487. [PubMed: 26733798]
- Pomrenze MB, et al., 2019 A Corticotropin Releasing Factor Network in the Extended Amygdala for Anxiety. *The Journal of Neuroscience.* 39, 1030. [PubMed: 30530860]
- Potter E, et al., 1992 The central distribution of a corticotropin-releasing factor (CRF)-binding protein predicts multiple sites and modes of interaction with CRF. *Proc Natl Acad Sci U S A.* 89, 4192–6. [PubMed: 1315056]
- Preil J, et al., 2001 Regulation of the hypothalamic-pituitary-adrenocortical system in mice deficient for CRH receptors 1 and 2. *Endocrinology.* 142, 4946–55. [PubMed: 11606463]

- Punn A, Levine MA, Grammatopoulos DK, 2006 Identification of signaling molecules mediating corticotropin-releasing hormone-R1alpha-mitogen-activated protein kinase (MAPK) interactions: the critical role of phosphatidylinositol 3-kinase in regulating ERK1/2 but not p38 MAPK activation. *Mol Endocrinol.* 20, 3179–95. [PubMed: 16959871]
- Qi X, et al., 2014 Sustained AAV-mediated overexpression of CRF in the central amygdala diminishes the depressive-like state associated with nicotine withdrawal. *Translational Psychiatry.* 4, e385–e385. [PubMed: 24755994]
- Qi X, et al., 2016 Overexpression of CRF in the BNST diminishes dysphoria but not anxiety-like behavior in nicotine withdrawing rats. 26, 1378–1389. [PubMed: 27461514]
- Quirarte GL, et al., 2007 Estradiol valerate and alcohol intake: dose-response assessments. *BMC Pharmacol.* 7, 3. [PubMed: 17335585]
- Rassnick S, et al., 1993 Microinjection of a corticotropin-releasing factor antagonist into the central nucleus of the amygdala reverses anxiogenic-like effects of ethanol withdrawal. *Brain Research.* 605, 25–32. [PubMed: 8467387]
- Rezvani AH, Levin ED, 2001 Cognitive effects of nicotine. *Biological Psychiatry.* 49, 258–267. [PubMed: 11230877]
- Ribeiro-Carvalho A, et al., 2009 Combined exposure to nicotine and ethanol in adolescent mice: effects on the central cholinergic systems during short and long term withdrawal. *Neuroscience.* 162, 1174–86. [PubMed: 19465085]
- Richardson HN, et al., 2008 MPZP: a novel small molecule corticotropin-releasing factor type 1 receptor (CRF1) antagonist. *Pharmacol Biochem Behav.* 88, 497–510. [PubMed: 18031798]
- Rinker JA, et al., 2017 Extended Amygdala to Ventral Tegmental Area Corticotropin-Releasing Factor Circuit Controls Binge Ethanol Intake. *Biol Psychiatry.* 81, 930–940. [PubMed: 27113502]
- Rivier C, Bruhn T, Vale W, 1984 Effect of ethanol on the hypothalamic-pituitary-adrenal axis in the rat: role of corticotropin-releasing factor (CRF). *J Pharmacol Exp Ther.* 229, 127–31. [PubMed: 6323684]
- Rodino-Janeiro BK, et al., 2015 Role of Corticotropin-releasing Factor in Gastrointestinal Permeability. *J Neurogastroenterol Motil.* 21, 33–50. [PubMed: 25537677]
- Ryabini AE, et al., 2012 Urocortins: CRF's siblings and their potential role in anxiety, depression and alcohol drinking behavior. *Alcohol.* 46, 349–57. [PubMed: 22444954]
- Sabino V, et al., 2006 Dissociation between opioid and CRF1 antagonist sensitive drinking in Sardinian alcohol-preferring rats. *Psychopharmacology (Berl).* 189, 175–86. [PubMed: 17047935]
- Sahuque LL, et al., 2006 Anxiogenic and aversive effects of corticotropin-releasing factor (CRF) in the bed nucleus of the stria terminalis in the rat: role of CRF receptor subtypes. *Psychopharmacology (Berl).* 186, 122–32. [PubMed: 16568282]
- Sakanaka M, Shibasaki T, Lederis K, 1986 Distribution and efferent projections of corticotropin-releasing factor-like immunoreactivity in the rat amygdaloid complex. *Brain Research.* 382, 213–238. [PubMed: 2428439]
- Samet JM, 2013 Tobacco Smoking: The Leading Cause of Preventable Disease Worldwide. *Thoracic Surgery Clinics.* 23, 103–112. [PubMed: 23566962]
- Sarnyai Z, Shaham Y, Heinrichs SC, 2001 The role of corticotropin-releasing factor in drug addiction. *Pharmacol Rev.* 53, 209–43. [PubMed: 11356984]
- Schreiber AL, Gilpin NW, 2018 Corticotropin-Releasing Factor (CRF) Neurocircuitry and Neuropharmacology in Alcohol Drinking. *Handb Exp Pharmacol.* 248, 435–471. [PubMed: 29374836]
- Schuckit MA, 2009 Alcohol-use disorders. *Lancet.* 373, 492–501. [PubMed: 19168210]
- Schulte MT, Ramo D, Brown SA, 2009 Gender differences in factors influencing alcohol use and drinking progression among adolescents. *Clin Psychol Rev.* 29, 535–47. [PubMed: 19592147]
- Seasholtz AF, Valverde RA, Denver RJ, 2002 Corticotropin-releasing hormone-binding protein: biochemistry and function from fishes to mammals. *J Endocrinol.* 175, 89–97. [PubMed: 12379493]

- Sesack SR, et al., 1989 Topographical organization of the efferent projections of the medial prefrontal cortex in the rat: An anterograde tract-tracing study with *Phaseolus vulgaris* leucoagglutinin. *The Journal of Comparative Neurology*. 290, 213–242. [PubMed: 2592611]
- Shaham Y, Erb S, Stewart J, 2000 Stress-induced relapse to heroin and cocaine seeking in rats: a review. *Brain Res Brain Res Rev*. 33, 13–33. [PubMed: 10967352]
- Shaham Y, de Wit H, 2016 Lost in Translation: CRF1 Receptor Antagonists and Addiction Treatment. *Neuropsychopharmacology*. 41, 2795–2797. [PubMed: 27312404]
- Sharpe AL, et al., 2005 Mice deficient in corticotropin-releasing factor receptor type 2 exhibit normal ethanol-associated behaviors. *Alcohol Clin Exp Res*. 29, 1601–9. [PubMed: 16205360]
- Sharpe AL, Phillips TJ, 2009 Central urocortin 3 administration decreases limited-access ethanol intake in nondependent mice. *Behav Pharmacol*. 20, 346–51. [PubMed: 19581799]
- Sherman JE, Kalin NH, 1988 ICV-CRH alters stress-induced freezing behavior without affecting pain sensitivity. *Pharmacol Biochem Behav*. 30, 801–7. [PubMed: 3265790]
- Sillaber I, et al., 2002 Enhanced and delayed stress-induced alcohol drinking in mice lacking functional CRH1 receptors. *Science*. 296, 931–3. [PubMed: 11988580]
- Silva SM, Madeira MD, 2012 Effects of chronic alcohol consumption and withdrawal on the response of the male and female hypothalamic-pituitary-adrenal axis to acute immune stress. *Brain Res*. 1444, 27–37. [PubMed: 22341871]
- Simms JA, et al., 2014 Intermittent access ethanol consumption dysregulates CRF function in the hypothalamus and is attenuated by the CRF-R1 antagonist, CP-376395. *Addict Biol*. 19, 606–11. [PubMed: 23362976]
- Slade T, et al., 2016 A Cross-National Examination of Differences in Classification of Lifetime Alcohol Use Disorder Between DSM-IV and DSM-5: Findings from the World Mental Health Survey. *Alcohol Clin Exp Res*. 40, 1728–36. [PubMed: 27426631]
- Slawecki CJ, et al., 2005 Increased CRF-like and NPY-like immunoreactivity in adult rats exposed to nicotine during adolescence: relation to anxiety-like and depressive-like behavior. *Neuropeptides*. 39, 369–77. [PubMed: 16038974]
- Smith GW, et al., 1998 Corticotropin releasing factor receptor 1-deficient mice display decreased anxiety, impaired stress response, and aberrant neuroendocrine development. *Neuron*. 20, 1093–102. [PubMed: 9655498]
- Smith PH, et al., 2016 Sex/gender differences in smoking cessation: A review. *Prev Med*. 92, 135–140. [PubMed: 27471021]
- Smith SM, Vale WW, 2006 The role of the hypothalamic-pituitary-adrenal axis in neuroendocrine responses to stress. *Dialogues Clin Neurosci*. 8, 383–95. [PubMed: 17290797]
- Sommer WH, et al., 2008 Upregulation of voluntary alcohol intake, behavioral sensitivity to stress, and amygdala *crhr1* expression following a history of dependence. *Biol Psychiatry*. 63, 139–45. [PubMed: 17585886]
- Sparta DR, et al., 2013 Binge ethanol-drinking potentiates corticotropin releasing factor R1 receptor activity in the ventral tegmental area. *Alcohol Clin Exp Res*. 37, 1680–7. [PubMed: 23763790]
- Squillaciotti C, et al., 2019 Urocortins in the mammalian endocrine system. *Acta Vet Scand*. 61, 46. [PubMed: 31585551]
- Stenzel-Poore MP, et al., 1992 Development of Cushing's syndrome in corticotropin-releasing factor transgenic mice. *Endocrinology*. 130, 3378–86. [PubMed: 1597149]
- Stinnett GS, Westphal NJ, Seasholtz AF, 2015 Pituitary CRH-binding protein and stress in female mice. *Physiol Behav*. 150, 16–23. [PubMed: 25731977]
- Sun N, Yi H, Cassell MD, 1994 Evidence for a GABAergic interface between cortical afferents and brainstem projection neurons in the rat central extended amygdala. 340, 43–64.
- Sutton RE, et al., 1982 Corticotropin releasing factor produces behavioural activation in rats. *Nature*. 297, 331–3. [PubMed: 6978997]
- Swordlow NR, Britton KT, Koob GF, 1989 Potentiation of acoustic startle by corticotropin-releasing factor (CRF) and by fear are both reversed by alpha-helical CRF (9–41). *Neuropsychopharmacology*. 2, 285–92. [PubMed: 2610824]

- Tabakoff B, Jafee RC, Ritzmann RF, 1978 Corticosterone concentrations in mice during ethanol drinking and withdrawal. *J Pharm Pharmacol.* 30, 371–4. [PubMed: 26769]
- Takahashi LK, 2001 Role of CRF(1) and CRF(2) receptors in fear and anxiety. *Neurosci Biobehav Rev.* 25, 627–36. [PubMed: 11801288]
- Takahashi LK, et al., 2001 Antagonism of CRF(2) receptors produces anxiolytic behavior in animal models of anxiety. *Brain Res.* 902, 135–42. [PubMed: 11384606]
- Thorsell A, Slawecki CJ, Ehlers CL, 2005 Effects of neuropeptide Y and corticotropin-releasing factor on ethanol intake in Wistar rats: interaction with chronic ethanol exposure. *Behav Brain Res.* 161, 133–40. [PubMed: 15904720]
- Timpl P, et al., 1998 Impaired stress response and reduced anxiety in mice lacking a functional corticotropin-releasing hormone receptor 1. *Nat Genet.* 19, 162–6. [PubMed: 9620773]
- Torres OV, et al., 2013 Behavioral, Biochemical, and Molecular Indices of Stress are Enhanced in Female Versus Male Rats Experiencing Nicotine Withdrawal. *Front Psychiatry.* 4, 38. [PubMed: 23730292]
- Torres OV, et al., 2015 Nicotine withdrawal increases stress-associated genes in the nucleus accumbens of female rats in a hormone-dependent manner. *Nicotine Tob Res.* 17, 422–30. [PubMed: 25762751]
- Torres OV, O'Dell LE, 2016 Stress is a principal factor that promotes tobacco use in females. *Prog Neuropsychopharmacol Biol Psychiatry.* 65, 260–8. [PubMed: 25912856]
- Tucci S, et al., 2003 Corticotropin releasing factor antagonist, alpha-helical CRF(9–41), reverses nicotine-induced conditioned, but not unconditioned, anxiety. *Psychopharmacology (Berl).* 167, 251–6. [PubMed: 12669178]
- Tunstall BJ, Carmack SA, 2016 Social Stress-Induced Alterations in CRF Signaling in the VTA Facilitate the Emergence of Addiction-like Behavior. *The Journal of Neuroscience.* 36, 8780. [PubMed: 27559161]
- U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration (SAMHSA), Center for Behavioral Health Statistics and Quality. (2018). National Survey on Drug Use and Health 2016 (NSDUH-2016-DS0001).
- Uribe KP, et al., 2019 Overexpression of corticotropin-releasing factor in the nucleus accumbens enhances the reinforcing effects of nicotine in intact female versus male and ovariectomized female rats. *Neuropsychopharmacology.*
- Uribe-Marino A, et al., 2016 Prefrontal Cortex Corticotropin-Releasing Factor Receptor 1 Conveys Acute Stress-Induced Executive Dysfunction. *Biol Psychiatry.* 80, 743–753. [PubMed: 27318500]
- Valadas JS, et al., 2012 Neuroprotection afforded by adenosine A2A receptor blockade is modulated by corticotropin-releasing factor (CRF) in glutamate injured cortical neurons. *J Neurochem.* 123, 1030–40. [PubMed: 23057965]
- Valdez GR, et al., 2003 Antagonism of corticotropin-releasing factor attenuates the enhanced responsiveness to stress observed during protracted ethanol abstinence. *Alcohol.* 29, 55–60. [PubMed: 12782246]
- Valdez GR, Sabino V, Koob GF, 2004 Increased anxiety-like behavior and ethanol self-administration in dependent rats: reversal via corticotropin-releasing factor-2 receptor activation. *Alcohol Clin Exp Res.* 28, 865–72. [PubMed: 15201629]
- Vale W, et al., 1981 Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin. *Science.* 213, 1394. [PubMed: 6267699]
- Van Den Eede F, Van Broeckhoven C, Claes SJ, 2005 Corticotropin-releasing factor-binding protein, stress and major depression. *Ageing Res Rev.* 4, 213–39. [PubMed: 15996902]
- Van Pett K, et al., 2000 Distribution of mRNAs encoding CRF receptors in brain and pituitary of rat and mouse. *Journal of Comparative Neurology.* 428, 191–212.
- Vandael D, Gouonk NV, 2019 Corticotropin releasing factor-binding protein (CRF-BP) as a potential new therapeutic target in Alzheimer's disease and stress disorders. *Transl Psychiatry.* 9, 272. [PubMed: 31641098]
- Varani AP, et al., 2012 Acute behavioural responses to nicotine and nicotine withdrawal syndrome are modified in GABA(B1) knockout mice. *Neuropharmacology.* 63, 863–72. [PubMed: 22727822]

- Vaughan J, et al., 1995 Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor. *Nature*. 378, 287–92. [PubMed: 7477349]
- Vendruscolo LF, Roberts AJ, 2014 Operant alcohol self-administration in dependent rats: focus on the vapor model. *Alcohol*. 48, 277–86. [PubMed: 24290310]
- Vigil P, et al., 2016 Influence of sex steroid hormones on the adolescent brain and behavior: An update. *Linacre Q*. 83, 308–329. [PubMed: 27833209]
- Vranjkovic O, et al., 2014 Stress-induced cocaine seeking requires a beta-2 adrenergic receptor-regulated pathway from the ventral bed nucleus of the stria terminalis that regulates CRF actions in the ventral tegmental area. *J Neurosci*. 34, 12504–14. [PubMed: 25209288]
- Wagner S, 2019 Urocortins and their unfolding role in mammalian social behavior. *Cell Tissue Res*. 375, 133–142. [PubMed: 30465153]
- Walker DL, Davis M, 2008 Role of the extended amygdala in short-duration versus sustained fear: a tribute to Dr. Lennart Heimer. *Brain Struct Funct*. 213, 29–42. [PubMed: 18528706]
- Wanat MJ, Bonci A, Phillips PE, 2013 CRF acts in the midbrain to attenuate accumbens dopamine release to rewards but not their predictors. *Nat Neurosci*. 16, 383–5. [PubMed: 23416448]
- Wang X, et al., 2002 Urocortin-deficient mice display normal stress-induced anxiety behavior and autonomic control but an impaired acoustic startle response. *Mol Cell Biol*. 22, 6605–10. [PubMed: 12192058]
- Weiss F, 2005 Neurobiology of craving, conditioned reward and relapse. *Curr Opin Pharmacol*. 5, 9–19. [PubMed: 15661620]
- Weller KL, Smith DA, 1982 Afferent connections to the bed nucleus of the stria terminalis. 232, 255–270.
- Westphal NJ, Seasholtz AF, 2006 CRH-BP: the regulation and function of a phylogenetically conserved binding protein. *Front Biosci*. 11, 1878–91. [PubMed: 16368564]
- Wills TA, et al., 2009 Sensitization, duration, and pharmacological blockade of anxiety-like behavior following repeated ethanol withdrawal in adolescent and adult rats. *Alcohol Clin Exp Res*. 33, 455–63. [PubMed: 19120055]
- Yang X, et al., 2008 Restraint stress and ethanol consumption in two mouse strains. *Alcohol Clin Exp Res*. 32, 840–52. [PubMed: 18336636]
- Yu G, et al., 2008 Nicotine self-administration differentially regulates hypothalamic corticotropin-releasing factor and arginine vasopressin mRNAs and facilitates stress-induced neuronal activation. *J Neurosci*. 28, 2773–82. [PubMed: 18337407]
- Zalutskaya AA, et al., 2007 Impaired adaptation to repeated restraint and decreased response to cold in urocortin 1 knockout mice. *Am J Physiol Endocrinol Metab*. 293, E259–63. [PubMed: 17456638]
- Zhang D, et al., 2012 Impact of Prefrontal Cortex in Nicotine-Induced Excitation of Ventral Tegmental Area Dopamine Neurons in Anesthetized Rats. 32, 12366–12375.
- Zhao L, et al., 1998 The structures of the mouse and human urocortin genes (Ucn and UCN). *Genomics*. 50, 23–33. [PubMed: 9628819]
- Zhao Z, et al., 2013 Amygdaloid corticotropin-releasing factor is involved in the anxiolytic effect of acupuncture during ethanol withdrawal in rats. *J Acupunct Meridian Stud*. 6, 234–40. [PubMed: 24139460]
- Zhao-Shea R, et al., 2015 Increased CRF signalling in a ventral tegmental area-interpeduncular nucleus-medial habenula circuit induces anxiety during nicotine withdrawal. *Nat Commun*. 6, 6770. [PubMed: 25898242]
- Zislis G, et al., 2007 Effects of the CRF receptor antagonist D-Phe CRF(12–41) and the alpha2-adrenergic receptor agonist clonidine on stress-induced reinstatement of nicotine-seeking behavior in rats. *Neuropharmacology*. 53, 958–66. [PubMed: 17976662]
- Zorrilla EP, et al., 2002 Effects of antalarmin, a CRF type 1 receptor antagonist, on anxiety-like behavior and motor activation in the rat. *Brain Res*. 952, 188–99. [PubMed: 12376179]
- Zorrilla EP, Koob GF, 2004 The therapeutic potential of CRF1 antagonists for anxiety. *Expert Opin Investig Drugs*. 13, 799–828.
- Zorrilla EP, et al., 2013 Behavioral, biological, and chemical perspectives on targeting CRF(1) receptor antagonists to treat alcoholism. *Drug Alcohol Depend*. 128, 175–86. [PubMed: 23294766]

Zorrilla EP, Logrip ML, Koob GF, 2014 Corticotropin releasing factor: a key role in the neurobiology of addiction. *Front Neuroendocrinol.* 35, 234–44. [PubMed: 24456850]

Zorrilla EPKG, 2005 The roles of urocortins 1, 2 and 3 in the brain, Steckler T, Kalin NH, Reul JM (eds) *Handbook of Stress and the Brain* (series title: *Techniques in the Behavioral and Neural Sciences*, Vol 15). Elsevier Science, New York, 2005, pp. 179–203

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Highlights

- Corticotropin releasing factor drives stress and anxiety related behaviors in alcohol and nicotine use disorders.
- Chronic nicotine and alcohol use results in the dysregulation of brain regions that are involved in stress and emotional systems.
- Sex-related behavioral differences increase the visibility of the necessity of sex-balanced studies in addiction research.




Figure 1. Distribution of corticotropin-releasing factor (CRF) and CRF₁ and CRF₂ receptors in the rat brain.

Corticotropin-releasing factor-positive regions are shown in green. CRF₁ receptor-positive regions are shown in blue. CRF₂ receptor-positive regions are shown in pink. A1, auditory cortex 1; A5, auditory cortex 5; Arc, arcuate nucleus; BAR, Barrington's nucleus; BLA, basolateral amygdala; BNST, bed nucleus of the stria terminalis; CeA, central nucleus of the amygdala; CB, cerebellum; CingCx, cingulate cortex; CoA, cortical amygdala; CPu, caudate putamen; DMH, dorsomedial hypothalamus; GPe, globus pallidus; Hip, hippocampus; IC, inferior colliculus; IO, inferior olive; IPN, interpeduncular nucleus; LC, locus coeruleus; LDTg, laterodorsal tegmental nucleus; LHA, lateral hypothalamus; LS, lateral septum; MeA, medial amygdala; MGN, medial geniculate nucleus; MV, medial vestibular nucleus; NAc, nucleus accumbens; NTS, nucleus of the solitary tract; OB, olfactory bulb; OccCx, occipital cortex; PAG, periaqueductal gray; ParCx, parietal cortex; PBn, parabrachial nucleus; PFC, prefrontal cortex; PG, pontine gray; Pir, piriform cortex; PPTg, pedunculopontine tegmental nucleus; PVN, paraventricular nucleus of the hypothalamus; R, red nucleus; RN, raphe nucleus; RTN, reticular thalamic nucleus; SC, superior colliculus; SNr, substantia nigra; SON, supraoptic nucleus; SP5n, spinal trigeminus nucleus; VMH, ventromedial hypothalamus; VTA, ventral tegmental area. Adapted from Henckens et al. (Henckens et al., 2016) and Valadas et al. (Valadas et al., 2012).




Figure 2. Intracellular signaling pathways for CRF₁ and CRF₂.

CRF, CRF-BP, Ucn1, Ucn2, and Ucn3 signaling is depicted. Thick lines denote preferential signaling and higher binding affinity. Dotted lines denote less preferential signaling and lower binding affinity. CRF₁ expression exhibits sex differences, in which females exhibit preferential signaling through G α s in situations with excess CRF, whereas males exhibit preferential signaling through β -arrestin 2. Corticotropin-releasing factor-binding protein interacts with CRF and Ucn1. CRF, corticotropin-releasing factor; CRF-BP, corticotropin-releasing factor-binding protein; Ucn1, urocortin-1; Ucn2, urocortin-2; Ucn3, urocortin-3; PLC, phospholipase C; IP3, inositol triphosphate; Ca²⁺, calcium; PKC, protein kinase C; G α s, Gs protein α subunit; PKA, protein kinase A; β -arrestin, β -arrestin 2; ERK, extracellular signal-regulated kinase; MAPK, mitogen-activated protein kinase; Rho, Rho guanosine triphosphatase; SRC, Src kinase.

Table 1.

Small-molecule and genetic manipulations of the CRF system in stress, anxiety, and dysphoria.

Target	Manipulation	Basal	Stress	Anxiety	Dysphoria	Other Behaviors	References
CRF	Agonist (i.c.v.)	↑	↑	↑	↑	Learning/memory Feeding Fear Reproduction Shock-induced freezing	(Sherman and Kalin, 1988) (Cullen et al., 2001) (Land et al., 2008)
CRF ₁ receptor	Antagonist (i.c.v.)	↓	↓	↓	↓	Depression Feeding	(Swerdlow et al., 1989) (Heinrichs et al., 1992) (Arborelius et al., 1999) (Zorrilla et al., 2002)
CRF ₂ receptor	Antagonist (i.c.v.)	↑/↓	↑/↓	↑/↓	↓	Feeding	(Pellemounter et al., 2000) (Cullen et al., 2001) (Takahashi et al., 2001) (Land et al., 2008)
CRF ₁ receptor	Genetic KO	↓	↓	↓	↓	Learning/memory Alcohol addiction Feeding	(Smith et al., 1998) (Timpl et al., 1998) (Bradbury et al., 2000) (Sillaber et al., 2002)
CRF ₂ receptor	Genetic KO	—	↑	↑	—	Depression Feeding	(Bale et al., 2000) (Coste et al., 2000) (Kishimoto et al., 2000)
CRF ₁ /CRF ₂	Genetic KO	↓	↓	↓♀ ↑♂	—	Grooming Sexually dysmorphic anxiety	(Preil et al., 2001) (Bale et al., 2002)
CRF	Genetic KO	↓	↓	—	—	Grooming Feeding	(Muglia et al., 1995)
CRF	Genetic overexpression	↑	↓	↑	—	Reproduction	(Stenzel-Poore et al., 1992) (Groenink et al., 2002)
CRF-BP	Genetic KO	—	—	↑	—	Weight gain Maternal aggression	(Karolyi et al., 1999) (Gammie et al., 2008)
CRF-BP	Genetic overexpression	—	↓	↑	—	Feeding Locomotor activity	(Lovejoy et al., 1998) (Burrows et al., 1998) (Stinnett et al., 2015)
CRF /CRF ₂ receptor	Optogenetic activation / inhibition	—	↓	↓	↓	Impairments in fear memory	(Anthony et al., 2014) (Fuzesi et al., 2016) (Henckens et al., 2017) (Kim et al., 2019)
CRF ₁ receptor	Genetic KO	↑	↑	↑	—	Increase in cortisol Slow stress recovery	(Jiang et al., 2018b)
CRF	Viral overexpression	↑	↑	↑	↑	Startle Depression	(Keen-Rhinehart et al., 2009)
Ucn1, Ucn2, Ucn3	Genetic KO	↓	↑	↑	—	Stress Startle Cold stress	(Wang et al., 2002) (Neufeld-Cohen et al., 2010) (Wagner, 2019) (Zalutskaya et al., 2007)

KO, knockout; i.c.v., intracerebroventricular; i.p., intraperitoneal. Adapted and updated from Vale and Bale (Bale and Vale., 2004).

Table 2.

Small-molecule and genetic manipulations of the CRF system in alcohol use disorder.

Target	Manipulation	Result	Reference
CRF	Genetic KO	KO mice consumed more alcohol than WT	(Olive et al., 2002)
CRF ₁ receptor	Genetic KO	KO mice did not exhibit increase in alcohol self-administration during withdrawal	(Chu et al., 2007)
		KO mice exhibited decrease in HPA recruitment, measured by corticosterone	(Pastor et al., 2008)
		KO mice exhibited increase in alcohol intake and increase in withdrawal-included alcohol self-administration	(Molander et al., 2012)
CRF ₂ receptor	Genetic KO	Alcohol intake was slightly reduced	(Sharpe et al., 2005)
		When stressed, KO animals consumed more alcohol than WT	(Sillaber et al., 2002)
		Alcohol intake was slightly reduced, but reduction was not maintained throughout the study	(Kaur et al., 2012)
CRF ₁ /CRF ₂ receptor	Genetic KO	KO mice did not exhibit alcohol-induced locomotor sensitization but exhibited decrease in HPA axis recruitment, measured by corticosterone in response to alcohol intake	(Pastor et al., 2008)
		Repeated forced swim increased alcohol intake	(Pastor et al., 2011)
CRF-BP	Genetic KO	No change in alcohol intake in mouse DID paradigm	(Ketchesin and Seasholtz, 2015)
CRF	Genetic overexpression	KO mice consumed less alcohol than WT	(Palmer et al., 2004)
CRF ₁ /CRF ₂ receptor	Agonist	Decrease in alcohol intake during two-bottle choice (i.c.v.)	(Bell et al., 1998)
		Decrease in alcohol intake in dependent vapor-exposed rats (i.c.v.)	(Thorsell et al., 2005)
		Increase in withdrawal-induced stress, measured by social interaction (i.c.v., intra-CeA, intra-BNST)	(Huang et al., 2010)
		Alcohol-withdrawn animals spent less time on the open arms of the elevated plus maze, indicating increase in the stress response (i.c.v.)	(Zhao et al., 2013)
		Decrease in social interaction as a measure of withdrawal-induced anxiety (i.c.v.)	(Overstreet et al., 2004b)
		Induction of alcohol reinstatement (i.c.v., intra-MRN)	(Le et al., 2002)
CRF ₁ /CRF ₂ receptor	Antagonist (D-Phe CRF _{12/41})	Decrease in anxiety-like behavior (i.c.v.)	(Valdez et al., 2003)
		Decrease in footshock-induced reinstatement (i.c.v.)	(Liu and Weiss, 2003)
		Decrease in alcohol-seeking behavior in dependent rats (intra-CeA)	(Funk et al., 2006)
		Decrease in alcohol withdrawal-induced alcohol self-administration (intra-CeA)	(Finn et al., 2007)
		Lower elevation of brain reward thresholds during alcohol withdrawal (i.c.v.)	(Bruinjeel et al., 2010)
CRF ₁ receptor	Antagonist (MTIP)	Decrease in anxiety-like behavior in elevated plus maze during acute alcohol withdrawal (i.p.)	(Gehlert et al., 2007)
CRF ₂ receptor	Agonist (Ucn3)	Decrease in alcohol intake after escalation (i.c.v.)	(Sharpe and Phillips, 2009) (Valdez et al., 2004)
		Increase in drinking in control animals (intra-CeA)	(Funk et al., 2007)

Target	Manipulation	Result	Reference
CRF ₂ receptor	Antagonist (astressin-2B)	Decrease in alcohol intake (intra-VTA) No effect (intra-CeA)	(Albrechet-Souza et al., 2015)
CRF-BP	Antagonist (CRF _[6-33])		
CRF ₁ /CRF ₂ receptor	Antagonist (α-helical CRF)	Decrease in anxiety-like behavior in elevated plus maze during acute alcohol withdrawal (i.c.v.)	(Baldwin et al., 1991)
		No change in anxiogenic-like effect of acute alcohol withdrawal (i.c.v.)	(Rassnick et al., 1993)
		Increase in alcohol preference in low-alcohol-preferring mice but not high-alcohol-preferring mice (i.c.v.)	(O'Callaghan et al., 2005)
		Decrease in alcohol intake in DID paradigm (i.c.v.)	(Lowery and Thiele, 2010)
		Decrease in anxiety-like behavior in elevated plus maze during acute alcohol withdrawal (intra-CeA)	(Rassnick et al., 1993)
CRF ₁ receptor	Antagonist (LWH-63)	Decrease in withdrawal-induced alcohol self-administration	(Sabino et al., 2006)
		Decreases in alcohol intake and blood alcohol levels (s.c.)	(Lowery-Gionta et al., 2012)
CRF ₁ receptor	Antagonist (antalarmin)	Decrease in acquisition of alcohol drinking and alcohol consumption (i.p.)	(Lodge and Lawrence, 2003)
		Decrease in alcohol self-administration and blockade of footshock-induced reinstatement in Marchigian Sardinian alcohol-preferring rats (i.p.)	(Hansson et al., 2006)
		Decrease in withdrawal-induced alcohol self-administration (i.p.)	(Chu et al., 2007)
		Decrease in withdrawal-induced alcohol self-administration in dependent but not nondependent rats (i.p.)	(Funk et al., 2007)
		Decrease in stress (yohimbine)-induced alcohol self-administration (i.p.)	(Marinelli et al., 2007) (Yang et al., 2008) (Ayanwuyi et al., 2013)
CRF ₁ receptor	Antagonist (CP-154,526)	Decrease in alcohol withdrawal-induced stress, measured by social interaction (i.p.)	(Overstreet et al., 2004b) (Overstreet et al., 2004a) (Breese et al., 2005) (Wills et al., 2009)
		Decrease in swim stress-induced alcohol intake in mice (i.p.)	(Lowery et al., 2008)
CRF ₁ receptor	Antagonist (CP-37,395)	Decrease in alcohol intake (i.p.)	(Giardino and Ryabinin, 2013) (Simms et al., 2014)
CRF ₁ receptor	Antagonist (CRA-1000)	Decrease in alcohol withdrawal-induced stress, measured by social interaction (i.p.)	(Knapp et al., 2004)
CRF ₁ receptor	Antagonist (MJL-1-109-2)	Decrease in withdrawal-induced alcohol self-administration in dependent but not nondependent rats (i.p.)	(Funk et al., 2007)
CRF ₁ receptor	Antagonist (MPZP)	Decrease in withdrawal-induced alcohol self-administration in dependent but not nondependent rats (i.p.)	(Gilpin et al., 2008)
		Decrease in withdrawal-induced alcohol self-administration in dependent but not nondependent rats (s.c.)	(Richardson et al., 2008)
CRF-BP	Antagonist (CRF _[6-33])	Decrease in alcohol intake (intra-VTA but not intra-CeA)	(Albrechet-Souza et al., 2015)

BP, binding protein; KO, knockout; WT, wildtype; CeA, central nucleus of the amygdala; BNST, bed nucleus of the stria terminalis; VTA, ventral tegmental area; DID, drinking-in-the-dark; HPA, hypothalamic-pituitary-adrenal; MRN, median raphe nucleus.

Table 3.

Small-molecule manipulations of the CRF system in nicotine use.

Target	Drug/compound	Result	Reference
CRF	Viral overexpression (AAV2/5-CRF)	Increase in CRF ₂ /CRF ₁ gene expression ratio and decrease in dysphoric-like behavior during nicotine withdrawal (bilateral intra-VNST)	(Qi et al., 2016)
		Increase in nicotine self-administration and CRF ₁ /CRF ₂ gene expression in females compared with males (bilateral intra-NAc)	(Uribe et al., 2019)
CRF ₁ receptor	Antagonist (R278995/ CRA-0450)	Prevention of elevation of brain reward thresholds during withdrawal- and stress-induced reinstatement of nicotine seeking (i.c.v.)	(Bruijnzeel et al., 2009)
		Prevention of elevation of brain reward thresholds during withdrawal (bilateral intra-CeA)	(Bruijnzeel, 2012a)
CRF ₁ receptor	Antagonist (R121919)	Decrease in thermal hyperalgesia during nicotine withdrawal and reinstatement of nicotine seeking (s.c.)	(Baiamonte et al., 2014)
CRF ₁ receptor	Antagonist (MPZP)	Prevention of nociceptive hypersensitivity and increase in nicotine intake following abstinence (bilateral intra-CeA)	(Cohen et al., 2015)
		Prevention of aversive effects of nicotine withdrawal and limited escalation of intake (bilateral intra-VTA)	(Grieder et al., 2014)
		Blockade of anxiety-like behavior during withdrawal and decrease in nicotine self-administration (s.c.)	(George et al., 2007)
CRF ₁ receptor	Antagonist (antalarmin)	Alleviation of anxiety-like behavior and decrease in neuronal activation (intra-IPN)	(Zhao-Shea et al., 2015)
CRF ₁ /CRF ₂ receptor	Antagonist (D-Phe CRF ₁₂₋₄₁)	Decrease in stress-induced reinstatement of nicotine seeking (i.c.v.)	(Zislis et al., 2007)
		Prevention of elevation of brain reward thresholds during nicotine withdrawal (i.c.v.)	(Bruijnzeel et al., 2007)
		Prevention of withdrawal-induced elevation of brain reward thresholds (intra-NAc and intra-CeA but not intra-BNST)	(Marcinkiewicz et al., 2009)
CRF ₂ receptor	Agonist (Ucn2, Ucn3)	Decrease in anxiety-like behavior following acute nicotine withdrawal (i.c.v.)	(Bagosi et al., 2016)
CRF ₂ receptor	Antagonist (astressin-2B)	No prevention of elevation of brain reward thresholds or stress-induced reinstatement of nicotine seeking (i.c.v.)	(Bruijnzeel et al., 2009)
CRF-BP	Antagonist (CRF ₁₆₋₃₃)	Blunting of weight gain during nicotine withdrawal (i.c.v.)	(Heinrichs et al., 1996)

BP, binding protein; BNST, bed nucleus of the stria terminalis; NAc, nucleus accumbens; IPN, interpeduncular nucleus.